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ABSTRACT OF THE DISSERTATION

Diabetes Mellitus and Limited Joint Mobility in the Upper Extremity
by
Kshamata Mukul Shah
Doctor of Philosophy in Movement Science
Washington University in St. Louis, 2014
Dr. Michael J. Mueller, Chairperson

Diabetes mellitus (DM) affects about 25 million people in the United States. Musculoskeletal
complications, especially those related to the upper extremity, are common and understudied in
people with DM. Limited joint mobility (LJM) is a systemic complication of DM believed to be
caused by thickening and stiffness of periarticular connective tissue due to non-enzymatic
accumulation of advanced glycation end-products (AGEs), and resultant cross-link formation in
the collagen. Specific implications of these structural changes on movement in people with DM
are not known. The objectives of this research were to characterize the upper extremity
movement impairments and limited joint mobility in people with diabetes mellitus and to
understand the relationships between AGEs, structural changes and movement impairments on
pain and disability in people with DM.
In Chapter 2, we examine the severity of upper extremity pain/disability, weakness and
limited joint mobility in a group of people diagnosed with DM attending an outpatient clinic. We
report that a striking majority of the patients with DM complained of shoulder pain and/or
disability, and that they had significant reductions in their shoulder range of motion, strength and
hand function measures as compared to non-DM controls. Further, these measures were related
viii

to the pain and/or disability. In Chapter 3, we examine the differences in shoulder movement
using 3-dimensional kinematics. We report substantial loss of humerus relative to scapula
motion, in particular, external rotation motion during elevation and rotation movements. In
Chapter 4, we examine the differences and relationships between a marker for AGEs, shoulder
structural changes, movement, and pain and/or disability. We report that the proxy measure for
skin AGEs, tendon thickness, movement impairments were higher in the DM group as compared
to controls and these measures were related to complaints of pain and disability.
In summary, our data indicate that shoulder and hand impairments are frequent, severe and
often associated with pain and disability. Shoulder LJM, in particular humerus relative to scapula
external rotation ROM, and strength deficits are significantly large in these individuals with DM
as compared to matched control participants. These studies, for the first time, examine the
relationship between an AGEs marker and functional measures as they relate to upper extremity
impairments and LJM in people with DM.
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CHAPTER 1:
Background and Significance

1

Diabetes Mellitus (DM) affects about 25 million people in the United States (1).
Musculoskeletal complications, especially those related to the upper extremity, are common and
understudied in people with DM (2-6). These musculoskeletal complications often lead to pain
and disability and may influence quality of life in individuals with DM (5-7). Therefore, studies
which focus on understanding musculoskeletal complaints and its relationship to physical
performance are necessary in these individuals. Some of the common impairments seen in the
upper extremity are limited joint mobility (LJM) at the shoulder and hand, frozen shoulder (also
referred as adhesive capsulitis), carpal tunnel syndrome and Dupuytren’s contracture. Several of
these abnormalities are related to connective tissue alterations in periarticular and skeletal
systems seen in people with DM.
LJM in people with DM is thought to be caused by thickening and increased stiffness in
the periarticular structures (8). Aging is also characterized by limitation in joint motion (9).
However, DM has been shown to have an additive negative effect on the joint stiffness seen with
advancing age (9,10). LJM is a systemic problem and has been documented at several joints in
the body including hand, shoulder, ankle and foot. Lower extremity LJM and associated tendon
pathologies have been associated with increased stresses on the plantar foot surface and is
thought to contribute to the development of foot ulcers (11,12). In the upper extremity, LJM has
been well documented at the hand but not at the shoulder (10,13-15). In its beginning stage, LJM
at the shoulder and hand may often be painless and go unnoticed. However, LJM may be a
precursor to severe upper extremity impairments associated with pain and/or disability (9,16,17).
In this introductory chapter, I will briefly overview upper extremity impairments in people with
DM and discuss contributing factors that may lead to these impairments (Fig.1).
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Prevalence of shoulder and hand impairments.
Studies have reported a higher prevalence of shoulder and hand impairments in people
with DM compared to those without DM (2,6,10,15-21). Prevalence of shoulder impairments and
pain in people with DM is about 11-50% compared to those without diabetes, 2 - 20% (2,6,7,1521). Milgrom et al. reported that individuals with DM had a much higher risk, 5.0 – 5.9 (95% CI
= 3.3, 8.4, P<0.001), for developing idiopathic frozen shoulder as compared to those without DM
(22). Additionally, frozen shoulder does not respond as well to treatment and symptoms tend to
last longer in individuals with DM (23). The prevalence of hand impairments is reported to be 875% in people with DM compared to about 0-26% in those without DM (15,19,21,24). Presence
of upper extremity impairments has also been linked with poor glycemic control and presence of
other diabetes related complications (2). A significant relationship has been found between the
prevalence of shoulder and hand impairments, indicating that they often co-exist (2,19,25).
Ramchurn et al. examined the prevalence of shoulder and hand problems in a group of people
with DM (N = 96; Mean Age = 55) compared to a group without DM (N = 100; Mean Age = 63)
(2). They found significant differences between groups, with higher prevalence of shoulder (25%
vs. 2%) and hand problems (63% vs. 12%) in people with DM. Another important finding was
that the glycemic control was poorer in individuals who had combined shoulder and hand
impairments (mean HbA1c 9.1%) versus those who had no impairments (mean HbA1c 8.0%).
Laslett et al. examined shoulder pain and disability [(measured via Shoulder Pain and Disability
Index (SPADI)] in people with DM and found that 45% reported shoulder pain and/or disability.
In a 12 month follow-up, 25% of individuals who reported no pain and/ or disability at baseline
developed clinically significant pain or disability (10% points change on the SPADI). 50% of the
patients with pre-existing pain and/or disability, developed clinically significant worsening of
3

pain and/or disability (6). Little is known about how self reported pain and disability relates to
upper extremity function measures. Therefore, there is a need for studies that examine the upper
extremity impairments and factors that contribute to these functional deficits.

Pathophysiologic factors.
One of the main mechanisms for LJM in diabetes is believed to be the formation of nonenzymatic advanced glycation end-products (AGEs) (8,26,27). Aging has also been associated
with AGEs accumulation. AGEs accumulate at a much higher rate in patients with DM as
compared to healthy adults (28). It is believed that the collagen changes lead to premature aging
in people with DM (28). The excessive glucose condenses with metabolic intermediates to form
AGEs. These AGEs are broken down only when the metabolic intermediates degrade. Thus,
AGEs tend to accumulate in tissues with low-protein turnover like the tendons, skin, ligaments
etc leading to increased cross-links (29,30). Additionally, specific AGE receptors (RAGE) have
been identified on the membrane of chondrocytes, tenocytes and fibroblasts (31,32) which when
activated, lead to accelerated AGE cross link formation in the collagen fibers of these tissues
(33,34). The cross-links in the tissues tend to make these structures thick, stiff, weak and
susceptible to injury (29,30).
AGEs also accumulate in body fluids such as serum and urine (28). Some of the methods
to measure AGEs in serum include high-performance liquid chromatography, enzyme-linked
immunosorbent assay and immunohistochemistry (28). However, these methods require blood
draws and expensive laboratory equipment to measure the level of AGEs. Skin AGEs provide a
good estimate of long term hyperglycemia. The half life of AGEs in the skin is about 15-20 years
4

and therefore, are a better indicator of this chronic hyperglycemia as compared to a single
measure of glycated hemoglobin which provides the glycemic exposure over 2-3 months (35,36).
Results from a study by Yian et al. provide further evidence for using biomarkers other than
HbA1c (37). They found that the HbA1c measure was not related to the prevalence of frozen
shoulder in a large sample of 1150 patients with diabetes and a diagnosis of frozen shoulder. The
skin AGEs can be measured non-invasively using the SCOUT DS device (VeraLight Inc.,
Albuquerque, NM), which uses ultraviolet light to excite and measure the fluorescence produced
by AGEs (38-40). In a validation study, the in-vitro AGEs levels in porcine skin biopsy samples
were related to the SIF (Skin Intrinsic Fluorescence) measured using spectrometry (41).
Additionally, research has shown that this in-vivo, non-invasive measure of the Skin Intrinsic
Fluorescence (SIF) has been related to various diabetes related complications like neuropathy,
increased arterial stiffness, nephropathy (38,42,43). However, the relationship between SIF and
shoulder structural changes, LJM and upper extremity function is unknown.

Structural Changes
Influence of AGEs accumulation can be seen on a variety of tissues, such as muscles,
bones and tendons. Haus et al. have shown that the accumulation of AGEs and resultant collagen
cross-links is significantly higher, approximately 200%, in muscle from healthy older individuals
as compared to younger individuals (44). DM has an additive negative effect on the
accumulation of AGEs and formation of cross-links. Higher concentrations of AGEs in the
intramuscular connective tissue may contribute to decreases in function. Changes associated with
AGEs accumulation are also seen in the bone. In a cadaver study, Tang and his colleagues
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showed that physical properties of cancellous bone, i.e. decreased energy, loss of stiffness etc.,
were impaired in ribosylated bone tissue samples with high AGEs as compared to control
samples, thus increasing its susceptibility of fracture (45). Odetti et al. found that the cortical
bone AGE level correlated negatively (P<0.01) with the degree of mass density loss (46).
Accumulation of AGEs in DM has been associated with impaired bone healing and osteoporosis
(47,48). Thus AGEs measurement may be a good indicator of bone strength and quality. High
AGEs concentrations have also been reported in cartilage tissues, possibly making the tissue
stiffer (35).
Upper extremity tendon changes have been studied using ultrasound. It is an easy and
relatively inexpensive method to evaluate tendon properties, particularly tendon thickness.
Studies have found increased thickness of long head of the biceps tendon and supraspinatus
tendon along with an increased incidence of tears in the supraspinatus tendon in people with DM
(9,49,50). The biceps and supraspinatus tendon changes are commonly studied because of their
important impact on movement, and because they can be measured easily using ultrasonography.
Further, the supraspinatus tendon is an abductor of the arm and contributes to external rotation
motion in an abducted position (50). Akturk et al. evaluated supraspinatus and biceps tendon
thickness in 150 individuals with DM (Mean age 50.2 (15)) and 94 without DM (Mean age 47.5
(14)) (50). They determined that individuals with DM had thicker supraspinatus and biceps (long
head) tendons compared to the control group (Supraspinatus tendon, 6.60 (6.58) mm vs. 4.91
(0.41) mm, P<0.01; Biceps tendon, 4.00 (1.05) mm vs. 2.95 (0.40) mm, P<0.01). Similarly,
Abate et al., measured supraspinatus and biceps (long head) tendon thickness changes in
asymptomatic elderly people with DM and compared to older people without DM (49). Tendon
thickness was significantly greater in people with DM compared to those without DM for the
6

supraspinatus (6.20 (0.09) mm vs. 5.20 (0.70) mm, P<0.01) and biceps tendon (4.00 (0.80) mm
vs. 3.20 (0.40) mm, P<0.01). Other changes observed in these tendons in people with DM
compared to those without are higher incidence of tears, increased degenerative changes and
calcifying tendinopathy (9,49,52,53). In addition to the structural properties, the physical
properties of the tendons in DM are also impaired. Tendon fiber sliding is decreased due to the
AGEs accumulation and collagen cross-links (54). AGE cross-link formation impacts the
synthesis of the extracellular matrix (55), further making the tissues stiff.
Other structural changes seen at the shoulder include fibrous contractures and dense
collagen matrix in the joint capsule and its adherence to the head of the humerus, rotator interval
area, and coracohumeral ligament at the shoulder joint in people with DM (52,56,57). Cystic and
sclerotic changes have been observed on the bony margins of the humeral head, glenoid and
acromion (53). These changes are twice as frequent in people with DM as compared controls.
However, the impact of these structural changes on movement and function is not understood.

Upper extremity movement and functional impairments.
Several studies have examined hand (24,25,58-61) or shoulder (9,16,17,62) impairments
in people with DM. But the combined influence of shoulder and hand impairments on function is
not clearly understood. Hand impairments in people with DM have been attributed to decreases
in grip strength and reduced sensation (25,58). Some studies have also shown that elderly
individuals with diabetes perform less well on a task of hand dexterity as compared to a group of
subjects without diabetes (25,61). Grip strength changes are frequently examined in people with
DM (25,58-61). High level AGEs accumulation in older women has been associated with low
7

grip strength values (63). Studies that examine shoulder muscles strength are lacking. A few
studies have examined LJM at the shoulder (glenohumeral joint) using goniometry and have
found differences in range of motion between people with diabetes and those without
(9,16,17,62). Abate et al. measured shoulder range of motion for flexion and abduction
movements in elderly people with DM and without DM. They found 20 degrees (P<0.01)
decrease in ROM for both motions in people with DM compared to those without DM (9).
Schulte et al. observed a significant decrease (6%, P<0.01) in composite shoulder ROM in
people with DM compared to the control group without DM (16). Similarly, Shinabarger reports
20 degrees decrease in abduction, and 6 degrees loss of lateral rotation ROM in people with DM
compared to those without DM (62). This study was conducted on small sample (10 with DM
and 9 without DM) and hence, significant differences in ROM were not observed for all
movements in the two groups. All these studies have used goniometry to detect ROM differences
at the glenohumeral joint between the two groups. However, with the use of goniometry only 2dimensional motion of the humerus relative to the thorax is quantified.
Combined scapulothoracic and glenohumeral motion is necessary to achieve full
humerus-to-trunk scapular plane elevation (40° anterior to the frontal plane) and perform daily
activities like personal hygiene and overhead reaching. In addition, the humerus-to-scapula
external rotation motion is critical for reaching overhead and daily activities like washing ones’
back and hair, dressing etc. With the use of three dimensional movement assessment, the motion
at the scapulothoracic and glenohumeral can be measured (64,65). Ludewig et al. assessed these
three dimensional motions using rigidly fixed electromagnetic sensors via transcortical bone pin
placement in the scapula and humerus (65) During relaxed standing, the scapula relative to the
trunk is internally rotated (~41° (2)), upwardly rotated (~6° (1)) and anteriorly tilted (~13.5° (2));
8

and the humerus relative to the scapula is externally rotated (~14° (4)) (65). During arm
elevation in the scapular plane, normal scapulothoracic movements, i.e. scapula relative to the
thorax, include – scapular internal rotation, upward rotation and posterior tilting; and normal
glenohumeral motions, i.e. humerus relative to scapula, include – humeral elevation and external
rotation. At maximum arm elevation in the scapular plane, compared to the relaxed position, the
scapula relative to the trunk will be less internally rotated (~35°), upwardly rotated (~51°) and
posteriorly tilted (~8°); and the humerus relative to the scapula will be elevated (~86°) and
externally rotated (~64°) (65).
Some studies have examined 3D kinematics in the shoulder joint in a heterogenic group
of people with frozen shoulder (66-71). These measures were compared to the uninvolved side in
the same individual or compared to measures in people without frozen shoulder. Overall, a
decrease in glenohumeral motion, especially elevation and external rotation has been observed
(66-71). Additionally, increased scapular upward rotation and reduced internal rotation have
been observed presumably to compensate for the glenohumeral hypomobility (68,70,71). These
studies examined movement deficits in people with diagnosed adhesive capsulitis, but no
mention of the diabetes status of the participants has been provided. To the best of our
knowledge, no study has examined the 3-dimensional shoulder movement in people with DM.
The accumulation of AGEs may also have a role to play in the increased evidence of
musculoskeletal pain in people with DM (28,72). Formation of AGEs and cross links induces
free radical formation and leads to oxidative stress. We hypothesize that glenohumeral and
scapulothoracic movement will be reduced in people with DM which will be related to
complaints of pain and/or disability in people with DM.

9

Purpose
The overall purpose of this study is to characterize upper extremity movement
impairments and LJM in people with DM, and to understand the relations between advanced
glycation end products (estimated using Skin Intrinsic Fluorescence (SIF)), structural changes,
movement impairments, and function in people with diabetes (DM). The hypothesized
progression of these complications is illustrated in Figure 1.
Specific Aim 1: (Chapter 2)
Establish the severity of upper extremity pain/disability, weakness and limited joint mobility in a
group of people diagnosed with DM attending an outpatient diabetes clinic.
Hypothesis 1: In a survey sample of individuals with DM, more than 20% of individuals
with DM will report pain and/or disability (operationally defined as total Shoulder Pain
and Disability Index (SPADI) score of more than 30%) in the upper extremity.
Hypothesis 2: The SPADI score will correlate inversely to shoulder range of motion
(ROM), strength and hand function measures.
Hypothesis 3: External rotation and abduction ROM and strength at the shoulder, and
hand function will be more impaired in people with DM than those without DM.

Specific Aim 2: (Chapter 3)
Determine differences in movement impairments in individuals with DM and those without DM.
Hypothesis 1: The group with DM will have reduced peak humerothoracic elevation,
scapulothoracic upward rotation, and glenohumeral rotations, especially external rotation
as compared to the group without DM.
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Specific Aim 3: (Chapter 4)
Determine differences and relationships in Skin Intrinsic Fluorescence (SIF), an indicator of
advanced glycation end–products, tendon thickness, movement impairments and upper extremity
function in people with DM versus non-DM controls.
Hypothesis 1: The SIF measure will be higher, the biceps and supraspinatus tendons will
be thicker, and upper extremity movement will be reduced in the DM group as compared
to the control group.
Hypothesis 2: SIF measure will be correlated to the tendon thickness and upper extremity
pain and/or disability, and negatively correlated to shoulder movement
Hypothesis 3: Significant amount of the variance of the upper extremity pain and/or
disability will be explained by the SIF, biceps tendon thickness, movement impairments
and shoulder flexor muscle strength.
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Figure 1 Theoretical model of upper extremity impairments in diabetes mellitus
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CHAPTER 2:
Upper Extremity Impairments, Pain and Disability in Patients with Diabetes Mellitus

This chapter is in review:
Shah KM, Clark BR, McGill JB, Mueller MJ. Upper Extremity Impairments, Pain and Disability
in Patients with Diabetes Mellitus. Physiotherapy
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ABSTRACT
OBJECTIVE: Determine the severity and relationships of Upper Extremity (UE) impairments,
pain and disability in persons with diabetes mellitus (DM); and compare UE impairments in
persons with DM to non-DM controls.
DESIGN: Case-control, and cross-sectional design.
SETTING: University-based, outpatient diabetes center and physical therapy research clinic.
PARTICIPANTS: Two hundred and thirty-six individuals with DM attending an outpatient
diabetes clinic completed the Shoulder Pain and Disability Index (SPADI) questionnaire. A
detailed shoulder and hand examination was conducted on a sub-group of 29 Type 2 DM
volunteers, and 27 age, sex and BMI matched non-DM controls.
INTERVENTIONS: None
MAIN OUTCOME MEASURES: Measures included the SPADI scores; passive shoulder range of
motion (ROM) and strength; grip strength; hand sensation; dexterity and hand limited joint
mobility (LJM).
RESULTS: Sixty-three % of persons with DM reported shoulder pain and/or disability [mean
SPADI score 21.7% (25.7)]. Compared to the non-DM controls, the DM sub-group had
reductions (P<0.05) in shoulder ROM (-9–15%); shoulder muscle strength (-11–25%); grip (14.8%) and key pinch strength (-12%). Persons with DM had a greater prevalence of decreased
sensation (26/27 vs.14/27) and hand LJM (17/27 vs.4/27) compared to the non-DM controls.
Total SPADI scores were negatively correlated (P<0.05) with shoulder ROM (r= -0.42 to -0.74)
and strength measures (r= -0.44 to -0.63) in the DM sub-group.
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CONCLUSIONS: UE impairments in this sample of patients with DM were common, severe, and
related to complaints of pain and disability. Additional research is needed to understand the
unique reasons for UE problems in people with DM and identify treatments to prevent them.
KEYWORDS: Diabetes Mellitus, Upper extremity, shoulder, hand
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Upper extremity (UE) musculoskeletal disorders are a common and understudied problem in
persons with diabetes mellitus (DM) (1-3). Clinical syndromes previously described in patients
with DM [2,3] include but are not limited to shoulder adhesive capsulitis or frozen shoulder,
limited joint mobility (LJM) at the hand, Dupuytren’s contracture and carpal tunnel syndrome.
Prior reports place the prevalence of shoulder impairments in people with DM significantly
higher at 11-50% (4-8) compared to those without diabetes, 2 - 20% (4,6-8). Similarly, the
prevalence of hand impairments is variably reported to be 8-75% (6,9-10) in people with DM
compared to about 0-26% (6,10) in those without DM. A significant relationship has been found
between the prevalence of shoulder and hand impairments, suggesting that they often co-exist
and may have a common mechanism [1,6,11].
LJM in DM is thought to be caused by non-inflammatory thickening and increased stiffness
in the periarticular structures (12). First observed at the hand, LJM may also occur at the
shoulder (4,9,13). In its beginning stage, LJM of the shoulder and hand may be painless and
therefore unnoticed. However, LJM may precede severe UE impairments associated with pain
and/or disability. The presence of LJM and associated impairments at the shoulder and hand may
have a significant impact on UE function in people with DM.
Studies have examined shoulder (7,14-16) or hand (11,17-20) impairments in patients with
DM, but the combined influence of shoulder and hand impairments on UE pain and disability has
not been studied. A few studies have examined LJM at the shoulder and report differences in
range of motion (ROM) between persons with DM and those without DM (7,14-16) but studies
of shoulder strength and UE function are lacking. The overall aim of this study was to:


Determine the severity of UE pain and disability in individuals with DM attending an
outpatient diabetes clinic. Pain and disability were estimated using the Shoulder Pain
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and Disability Index (SPADI) (21,22), a self-report questionnaire which has been
previously used in patients with DM (5,7).


Compare shoulder ROM, strength and hand function measures on a subgroup of
people with DM and those without DM (matched for age, sex, body mass index
(BMI)).



Determine the relationship between the shoulder and hand strength and joint mobility,
and UE pain and disability in a subgroup of people with DM.

Understanding these outcomes and relationships should help to focus future rehabilitation
research and interventions to reduce the severity of UE impairments and disability in people with
DM.

METHODS
Participants:
We mailed a flyer containing the SPADI questionnaire, demographic information sheet,
cover letter, and consent to 336 individuals with DM enrolled in the Diabetes and Research
Training Center Prevention and Control Core patient database. The flyer also had a section for
the participants to indicate if they wished to be contacted for an UE examination. The cover
letter encouraged the participants to respond even if they did not have pain and/or disability. We
also obtained consent and distributed 103 questionnaires at the Diabetes Center to unselected
DM patients willing to complete the flyer. A total of 236 patients completed the flyer (Table 1).
The SPADI, a self-report questionnaire, contains a total of 13 items, divided into two sub-groups
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i.e. pain (5 items) and disability (8 items) (21,22). Each item is scored from 0-10 and scores for
each sub-group are averaged and converted to a percentage (22). The total SPADI scores are an
average of the two sub-scores and range from 0% to 100%; higher score indicates more pain and
disability. The SPADI has excellent reliability, includes questions on shoulder and hand
function, and is easy (<5 minutes) to administer (23).
A detailed shoulder and hand evaluation was completed on 1) a sub-group of the first 29
individuals with type 2 DM who agreed to participate when contacted by the research team and
2) 27 individuals without DM and current shoulder pain/disability, and were well matched for
age, sex, weight, height, BMI and handedness (P>0.05, Table 2). We anticipated a high effect
size (Cohen’s d= 0.8) for all key outcome variables (shoulder ROM and strength, and hand
function). A sample size of 27 in each group was predicted to find statistical differences between
the groups [Statistical power level = 0.8 and alpha = 0.05 (two tailed)]. Data from all participants
in the DM group were used to examine the relationship between the SPADI and the UE clinical
measures. The control subjects were recruited from a university database of healthy volunteers.
Participants in both groups were above 35 years of age and did not have recent (past six months)
shoulder injuries, known rotator cuff tears, or neck pain. All participants read and signed the
consent form approved by the institutional review board.
Clinical examination on both upper extremities on all participants was completed by the
same physical therapist (KMS). For all evaluation measures, an average of two trials was used
for data analyses with adequate rest pauses between trials.
Shoulder Evaluation:
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Shoulder ROM was measured using a 12” plastic goniometer (Baseline ®, Elmsford, NY)
and standardized methods with established reliability (24-27). Active ROM was measured for
flexion, abduction and external rotation ROM with the subject seated on a stool without a
backrest (24,25). External rotation movement was measured with the arm close to the body and
elbow bent at 90° (27). Maximal passive ROM in the pain free range was measured for shoulder
flexion, abduction, internal rotation and external rotation with the subject in supine position
(24,26). The arm rotations were measured with arm abducted to 90°, and elbow in 90° flexion
and neutral rotation (25,26). The active ROM helped ‘loosen up’ the joint prior to the passive
movement and the passive ROM measurement helped clarify joint limitations that may not be
due to active movements.
We measured the isometric strength (in kilograms) of the shoulder flexor, abductor and
rotator muscles using a hand-held, digital strain-gauge dynamometer (Microfet ™, Hoggan
Health, UT). The patient was in supine position and standard stabilization (provided by the
tester) and test positions were used (28-30). A “make” test procedure was used, where the
subject was asked to ramp up the contraction for about 2 seconds and hold the maximum effort
against the resistance applied by the therapist for 4-5 seconds. Rest periods were provided
between the trials. Each muscle action was measured in a gravity-neutralized position while
holding the dynamometer perpendicular to the limb.
Hand Evaluation:
The grip and pinch strength (key pinch and palmar) were measured in kilograms using a
Jamar dynamometer (J. A. Preston, Grand Rapids, MI) and a pinch gauge (B&L Engineering,
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Santa Ana, CA) respectively. The subject was seated with their shoulder adducted and in neutral
rotation, elbow flexed at 90° and forearm in neutral position (31).
The Nine-Hole Peg (Sammons Preston, Cedarburg, WI) test was used to measure dexterity
using standardized methods (11). The participant placed pegs in nine holes using one hand at a
time and removed them as quickly as possible one at a time. The total time to complete each test
was noted.
Hand LJM was quantified via the ‘Prayer Sign’. Subjects’ inability to press their palms
together completely without a gap remaining between opposed palms and fingers was termed
‘Positive Prayer Sign’ (Figure 1) (9).
Light touch perception was measured in the peripheral nerve supply of the hand using
Semmes Weinstein monofilaments (TactileTM sensory evaluator, Baseline ®, Elmsford, NY)
(20,32,33). Filaments ranging from 2.83 - 6.65 (0.07g - 330g force) were applied until they bent
and #6.65 was applied just to bending. The smallest perceivable monofilament was noted. The
grading for the monofilaments was as follows: intact (2.83), diminished light touch (3.61),
diminished protective sensation (4.31), loss of protective sensation (4.56– 6.65) (32,33).

Statistical Analyses:
Statistical analyses were performed using IBM Statistical Package for the Social Sciences
Software (SPSS Inc, Chicago, IL) for Windows (19.0); alpha level was set at P<0.05.
Descriptive statistics (percentages, means, standard deviations and percent changes) were used to
describe outcome measures. There were no significant differences between right and left UE
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evaluation measures in persons with DM, therefore only data from the right UE were included in
statistical analyses. The active and passive ROM for flexion and abduction motions were not
statistically different, therefore only passive ROM was included in further analysis. The data for
the active external rotation ROM has been reported in the results. All data were analyzed using
the Shapiro-Wilk test for normality and non-parametric tests were used when necessary.
Student’s t-tests and chi-square test (for hand LJM) were used to examine group differences in
the UE clinical measures; and Pearson’s correlation co-efficient was used to examine the
relationship between the total SPADI score and UE measures. Further, a hierarchical multiple
regression analysis was performed using the total SPADI scores as the dependent variable and
the shoulder abduction ROM and hand grip strength as predictors. We chose these measures a
priori because 1) abduction ROM measure provides an indication of one’s ability to perform a
variety of shoulder movements, and 2) grip strength measure is often used as a surrogate measure
for decreased UE strength and as a predictor of disability (19,34).

RESULTS:
Flyer:
236 flyers, containing the SPADI and demographic information were collected on persons
with DM. 133 flyers were collected via mailing and 103 flyers were collected at the Diabetes
Clinic. The overall response rate to the flyer was 53.8 % (236/439). Subject characteristics from
the flyer are listed in Table 1. Overall, 63% (149/236) reported shoulder pain and/or disability
(mean total SPADI score 21.7% (25.7). 30% (72/236) reported substantial pain and/or disability,
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operationally defined as a SPADI score of more than 30% (mean total SPADI score 56.14%
(16.55)) (Appendix, Figure 1).
Upper Extremity Evaluation:
Subject characteristics of the DM and control groups matched for age, weight, height, and sex
are represented in Table 2.
Shoulder Measures: Shoulder flexion, abduction, external rotation passive ROM were reduced
by -9 % to -15.4 % (P<0.01, Table 2, Fig. 2) in the DM group compared to those without DM.
Active external rotation ROM was also reduced in the DM group (59.8° (10.7) vs. 66.8° (8.7);
P=0.01). Mean shoulder flexors, external and internal rotators strength were reduced by -10.9 %
to -25.5 % ( P<0.05, Table 2, Fig. 2) in the DM group compared to the control group.
Hand Measures: Grip strength and key pinch strength were decreased by -14.8% and -12.1%
(P<0.05), respectively, in the DM group compared to the non-DM cohort (Table 3, Fig. 2). Hand
LJM, indicated by ‘positive’ prayer sign, was more prevalent in those with DM compared to
those without (17/27 vs. 4/27, P=0.006, Table 3). Peripheral sensation was more frequently
impaired in those with DM compared to those without DM (26/27 vs. 14/27, Table 3).
Relationship between SPADI scores and upper extremity evaluation measures:
There was a strong negative correlation between the total SPADI scores and shoulder ROM
measures (r = -0.42 to -0.74, P<0.05), and shoulder muscles strength (r = -0.44 to -0.63, P<0.05,
Table 2) in the DM subgroup. 68% (P<0.01) of the variance of the total SPADI scores was
explained by the shoulder abduction ROM (R2 change = 0.55, P≤0.001) and grip strength (R2
change = 0.13, P=0.003).
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DISCUSSION:
Sixty-three% of individuals with DM reported shoulder pain and/or disability. 31% of the
DM patients had substantial pain and/or disability, defined in this study as a total SPADI score of
more than 30%. Upper extremity impairments in this sample of patients with DM attending an
outpatient Diabetes Center were common, severe, and related to complaints of pain and disability
(Tables 1, 2, 3 and Fig. 2). Shoulder ROM, especially external rotation and abduction, and
strength were reduced (8-25%) and negatively correlated (r = -0.42 to -0.68) to SPADI scores,
indicating the close relationship between shoulder LJM and strength, and UE function.
This is the first study to comprehensively report shoulder and hand impairments, and their
relationship with UE function in people with DM. Shinabarger (14) measured shoulder active
ROM in a small group of people with Type 2 DM (N=9) and Abate M et al (16) measured
passive ROM for flexion and abduction ROM, and report a 2-14% reduction in ROM compared
to those without DM. Adequate shoulder ROM, especially external rotation and abduction, and
strength are particularly important for completing tasks of daily living like reaching an overhead
shelf, grooming, and self care. Interestingly, in a subgroup of individuals with DM who had a
SPADI score of 0% (N=5), we found that shoulder ROM and strength were reduced by 8 -10%
and 5-13%, respectively, compared to individuals without DM and similar SPADI scores
suggesting that early losses may not be recognized by the patient.
Hand strength, mobility and sensation were decreased in people with DM compared to those
without DM, contributing to the global UE dysfunction in people with DM. Savas et al noted
similar decreases in grip (16%) and key pinch (9%) strength in individuals with DM compared to
those without DM (17). Significant differences in grip strength and sensation in the hand also
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have been recorded by other studies (11,18-20,35). Individuals with diminished protective
sensation may have decreased hand function, leading to difficulty in manipulation of small
objects and a tendency to drop objects (11,32). Hand dexterity, although reduced, was not
significantly different between the two groups in this study. Redmond et al reported significant
association between Disability of Arm Shoulder and Hand (DASH) scores and grip strength,
dexterity and BMI measures (R2 = 0.38) (11). In our study, 68% (P<0.01) of the variance in the
total SPADI scores was explained by abduction ROM and grip strength verifying that
measurable UE impairments are related to complaints of pain and/or disability. Previous studies
have failed to report the combined influence of shoulder and hand impairments on overall UE
function. The results from this study support our hypothesis that shoulder and hand impairments
impact UE function. Future studies in people with DM should focus on studying the shoulder and
hand as one functional unit.
This study characterizes insidious UE impairments in people with DM, and these results may
further help develop appropriate treatment strategies for these individuals. If impairments are
identified early, simple exercises that focus on improving UE ROM, especially external rotation
and elevation, and strength may be administered to minimize or prevent further detrimental
changes in patients with DM. In one of the few prospective studies of shoulder disorders in DM,
Laslett et al reported that 45% of people with DM had shoulder pain and/or disability, as
measured via the SPADI (5). In a 12 month follow-up, 25% of individuals who reported no pain
and/ or disability at baseline developed clinically significant pain or disability (10% points
change on the SPADI). Additionally, of the patients with pre-existing pain and/or disability, 50%
developed clinically significant worsening of pain and/or disability. We postulate that DM
causes loss of ROM and strength that may hit a “threshold” leading to severe UE limitations and
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disability. Further research is necessary to understand the factors that may be associated with the
progression of UE impairments in people with DM and if exercise can be used to help prevent
the problems.
This study adds to the growing body of research describing LJM in the upper and lower
extremities of people with DM (16,36). The underlying mechanisms that lead to these systemic
musculoskeletal changes need further investigation. The primary mechanism for LJM is believed
to be the condensation of glucose and metabolic intermediates to form advanced glycation endproducts (AGE) (12,37). AGEs accumulate in tissues with low protein turnover such as skin and
tendons, and lead to cross-links making the tissues thicker, stiffer, weaker and therefore, more
prone to injury (38). These structural changes may affect joint movement. Although detailed
kinematic studies have been performed on the shoulders of people with adhesive capulitis (39),
additional research is needed to understand the 3D glenohumeral and scapulothoracic ROM
deficits unique to diabetes and LJM. Investigating the relationships between AGEs, structural
changes and UE movement impairments will provide insights to the UE musculoskeletal
problems in people with DM. A better understanding of the physiological and movement related
factors associated with diabetic musculoskeletal problems may lead to enhanced treatment
strategies (i.e., exercise or pharmalogical) to manage or even prevent the problems.
Study Limitations
We purposed to collect data from a representative sample of patients with DM attending an
outpatient clinic but there may have been a sampling bias between the respondents and nonrespondents in the questionnaires. To minimize this bias, we 1) mailed a cover letter that
encouraged the participant to respond even if they did not have pain/disability, and 2) collected
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the SPADI information at the diabetes clinic from DM patients, not selected by their
pain/disability levels. While UE impairments were evaluated in individuals with DM, who had
varying levels of pain and/or disability, there is also the possibility of sampling bias. We
matched the diabetes and control groups for age, weight, height, BMI, sex and handedness which
allowed us to examine group differences (DM vs. no DM) in UE function with greater
confidence. Lastly, we cannot comment on the temporal relationship of the development and
progression of UE problems as this was a cross-sectional study. Additional research is needed to
determine more clearly if the insidious loss of shoulder ROM is a precursor to severe shoulder
disability.
CONCLUSIONS:
A substantial majority (63%) of individuals with DM in this study report shoulder pain
and/or disability. Compared to individuals without DM, persons with DM had considerable LJM
and strength deficits at the shoulder and hand, and decreased sensation. Complaints of UE
functional deficits, and pain and/or disability were highly correlated with shoulder and hand
ROM, especially shoulder external rotation and abduction, and strength deficits. These
impairments, which may be overlooked in the rehabilitation clinic setting, are related to
functional deficits and may lead to difficulty in performing daily life activities. Further studies
are needed to better characterize UE movement impairments in DM, and the pathologic
mechanisms and methods for prevention and treatment.
Acknowledgements: The authors thank Dr. Catherine E. Lang for contributing to the study
design and methods, and Ms. Lori Buechler for helping with data collection.
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Table 1. Demographic and SPADI information from the survey flyers.
Total survey flyers

236
Mailed-in 133

Completed at Diabetes Clinic 103
Age (yrs)

61.4 (11.9)
2

BMI (kg/m )

31.7 (6.9)

Male

47.4 % (112)

Diabetes Type 2
Duration of diagnosed diabetes (yrs)

72.9 % (172)
16.4 (12.1)

HbA1c (%)

7.37 (1.3)

SPADI Pain score
(0-100%)
SPADI Disability score
(0-100%)
Total SPADI score
(0-100%)
SPADI equal to 0%

26.3 (29.7)
(Range: 0 – 100 %)
17.2 (23.7)
(Range: 0 – 90 %)
21.7 (25.7)
(Range: 0 – 93.2 %)
36.8 % (87)

SPADI not equal to 0%

63.2 % (149)

SPADI over 30%

30.5 % (72)

Data represented as means (SD) or % (N) unless otherwise indicated; SPADI = Shoulder Pain
and Disability Index
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Table 2. Subject characteristics and Shoulder evaluation measures
Diabetes
group
27
65.7(8.9)
101.1 (21.2)
1.7 (0.09)
33.2 (5.5)
17/10
26/1
37.1 (27.9)

Control
group
27
64.4(8.7)
98.1(16.4)
1.7 (0.10)
33.3 (6.0)
17/10
26/1
0

Significance a

R
L

154.4 (24.6)
149.2 (29.7)

169.9 (5.7)
170.2 (4.9)

P ≤ 0.001#

-0.68#

R
L

147.4 (25.8)
141.3 (29.4)

170.4 (5.2)
169.6 (6.4)

P ≤ 0.001#

-0.74#

R
L

66.5 (12.8)
60.9 (20.3)

78.5 (4.5)
75.8 (5.4)

P ≤ 0.001#

-0.51#

R
L

74.6 (10.7)
72.9 (15.5)

79.0 (7.5)
81.5 (4.9)

P = 0.10

-0.42*

R
L

10.9 (3.9)
9.8 (3.8)

14.7 (4.2)
13.9 (4.3)

P ≤ 0.001#

-0.44*

R
L

9.1 (3.8)
8.5 (2.8)

10.5 (2.4)
9.7 (2.3)

P = 0.15

-0.56#

R
L

10.8 (3.3)
9.5 (3.8)

13.1 (3.7)
11.1 (2.8)

P = 0.02*

-0.51#

R
L

12.1 (3.8)
11.3 (4.8)

13.6 (3.5)
14.5 (3.3)

P = 0.048*

-0.63#

Measure (units)
Number of subjects
Age (yrs)
Weight (kgs)
Height (m)
BMI (kg/m2)
Sex (M/F)
Dominance (R/L)
SPADI score (%)
Passive ROM (deg):

Correlation with total
SPADI scores b

P = 0.64
P = 0.99
P = 0.93
P = 0.93

Flexion

Abduction

External Rotation

Internal Rotation c

Strength (kgs):
Flexors

Abductors

External Rotators

Internal Rotators
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Data represented as means (SD) unless otherwise indicated.
a = P values were determined by using Independent Sample Student’s t-test; * indicates P <0.05;
# indicates P<0.01.
b = Correlation between the total SPADI scores and shoulder ROM and strength measures was
determined using Pearson’s correlation coefficient (N=29); * indicates P <0.05; # indicates
P<0.01.
c = Non-parametric tests were used - Mann Whitney U test and Spearman’s Correlation.
R = Right; L = Left; ROM = Range of Motion; SPADI = Shoulder Pain and Disability Index
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Table 3. Hand evaluation measures
Diabetes
group

Control group

Significance a

Correlation
with total
SPADI
scores b

R
L

28.4 (9.7)
27.1 (10.0)

33.4 (10.3)
32.3 (9.5)

P= 0.045*

-0.28

R
L

9.2 (5.4)
7.7 (2.5)

10.5 (2.3)
8.6 (2.0)

P = 0.04*

-0.28

R
L

6.7 (2.2)
6.7 (2.6)

7.3 (1.9)
7.3 (2.5)

P = 0.32

0.10

R
L

23.8 (3.7)
25.0 (4.7)

22.4 (3.4)
22.9 (3.0)

P = 0.056

0.14

Measure (units)

Grip Strength (kgs):

Key Pinch Strength (kgs):

Palmar Pinch Strength (kgs):

9 Hole Peg Test (sec) c:

Hand sensation (N):
Intact
Diminished Light Touch

1

13

17

13

Diminished Protective Sensation

8

1

Loss of protective sensation

1

0

Prayer sign (N):
10
23
Negative
17
4
Positive
Data represented as means (SD) unless otherwise indicated.

P = 0.006 d

a = P values were determined by using Independent Sample Student’s t-test; * indicates P <0.05;
# indicates P<0.01
b = Correlation between the total SPADI scores and shoulder ROM and strength measures was
determined using Pearson’s correlation coefficient (N=29).
c = Non-parametric tests were used - Mann Whitney U test and Spearman’s Correlation.
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d = Significance determined by Chi-Square test
R = Right; L = Left; SPADI = Shoulder Pain and Disability Index
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Figure 1 ‘Positive Prayer Sign’

‘Positive Prayer Sign’ is the subjects’ inability to press their palms together completely without
a gap remaining between opposed palms and fingers.
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Figure 2 Shoulder and Hand evaluation measures in DM group as compared to control group

Shoulder and Hand evaluation measures
0.00%

Percent difference between DM group
compared to control group

Flx_ROM Abd_ROM ER_ROM

IR_ROM

Flx_Str

Abd_Str

ER_Str

IR_Str

Grip_Str

-5.00%

Key Pinch
Str

-10.00%
-15.00%

#

-20.00%

DM group

*

#
#

*
*

-25.00%
-30.00%

*

#

-35.00%

Data represented as mean percent difference (SD)
* indicates P < 0.05; # indicates P < 0.01; P values were determined by using Independent Sample Student’s t-test and MannWhitney test (for IR ROM); Flx = Flexion; Abd = Abduction; ER = External rotation; IR = Internal rotation; ROM = Range of
motion; Str = Strength; DM = Diabetes Mellitus
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Shoulder Limited Joint Mobility in People with Diabetes Mellitus
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People with Diabetes Mellitus.
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ABSTRACT

Background: Limited joint mobility (LJM) at the shoulder has not been examined using 3dimensional kinematics in individuals with diabetes mellitus (DM). The purpose of this study
was to determine the differences in shoulder kinematics between a group with DM and those
without DM.
Methods: Fifty-two participants were recruited, 26 with DM and 26 non-DM controls (matched
for age, BMI and sex). Three-dimensional position of the trunk, scapula and humerus were
collected using electromagnetic tracking sensors during scapular plane elevation and rotation
movements.
Findings: Glenohumeral external rotation was reduced by 11.1º - 16.3º (P<0.05) throughout the
elevation motion in individuals with DM as compared to controls. Peak humerothoracic
elevation was decreased by 10-14°, peak external rotation, with the arm adducted and abducted,
was decreased, by16º- 22º, respectively in the DM group compared to controls (P<0.05). The
scapulothoracic motion and glenohumeral internal rotation, with arm at the side and arm
abducted, was not different between the two groups.
Interpretation: Shoulder LJM, in particular decreased external rotation, was seen in individuals
with DM as compared to control participants. Future research should investigate causes of
diabetic LJM and strategies to prevent or improve shoulder LJM and additional detrimental
changes in movement and function.
Keywords: shoulder, limited joint mobility, kinematics, diabetes mellitus
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Musculoskeletal complications, especially those related to the upper extremity, are a fairly
common and yet understudied problem in people with DM (1,2). Some of the common shoulder
problems include limited joint mobility (LJM) and frozen shoulder. LJM is a systemic problem
which has been studied at the relatively small joints of the hands, feet and ankles (3,4); however,
the specific joint motion limitations at the shoulder are not well documented. Milgrom et al.
reported that individuals with DM had a much higher risk, 5.0 – 5.9 (95% CI = 3.3-8.4,
P<0.001), for developing idiopathic frozen shoulder as compared to those without DM (5).
Frozen shoulder is characterized by presence of severe limitation of range of motion, pain and a
slow recovery process. LJM at the shoulder is often painless but may be the precursor to more
severe upper extremity impairments and functional limitations (6-8). It is believed to result from
metabolic abnormalities effecting connective tissues in periarticular and skeletal structures
(3,9,10).
Shoulder range of motion (ROM) has been studied by conventional goniometry in persons
with diabetes and compared to non-diabetic controls, with findings that abduction and ER ROM
was decreased, 138 (20)º versus 158 (21)º, and 83 (8)º versus 89 (4)º, respectively (6,11).
Goniometry measures 2-dimensional motion of the humerus relative to the thorax, ignoring the
glenohumeral and scapulothoracic joints, which are assessed using 3-dimesional kinematic
measures. In studies of persons with heterogeneous causes of frozen shoulder, 3D kinematics
has demonstrated a decrease in glenohumeral motion, especially elevation and external rotation
when compared to the uninvolved side in the same individual or unaffected controls (12-15).
Overall, a decrease in glenohumeral motion, especially elevation and external rotation has been
observed. Additionally, increased scapulothoracic upward rotation and internal rotation has been
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observed. No study has examined the insidious shoulder LJM at the glenohumeral and
scapulothoracic joints that occurs in asymptomatic or minimally symptomatic people with DM.
The purpose of this study was to determine the differences in shoulder kinematics in
individuals with DM as compared to non-DM controls. We hypothesized that scapulothoracic
upward rotation, and glenohumeral motion external rotation would be reduced during scapula
plane elevation in people with DM as compared to the non-DM controls. The glenohumeral
rotational movements, especially external rotations, would be reduced during rotation motion
with arm at the side of the body and with the arm in an abducted position. We chose to evaluate
these motions because the scapulothoracic upward rotation is the most dominant scapula motion
during elevation, and glenohumeral external rotation is important to clear the greater tuberosity
of the humerus from the subacromial space during overhead reaching motions (16,17). For
rotation movements, we focused on the humerus relative to scapula motion, as this represents
actual glenohumeral motion and these motions are important for completing activities of daily
living (18).

METHODS:
We recruited 26 participants with Type 2 DM and 26 control participants matched for age,
body mass index and sex and who did not have shoulder pain. Subjects were recruited from the
Washington University Diabetes Center and the Volunteers for Health database at Washington
University School of Medicine. The main focus of this study was to examine the kinematic
differences between individuals with DM who were at risk for systemic LJM versus those
without DM. Characteristics associated with LJM include duration of DM (1,2) and a positive
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prayer sign, described as the inability to press their palms together completely without a gap
remaining between opposed palms and fingers (19). Therefore, inclusion criteria for the DM
group were: duration of diagnosed DM over 10 years or a ‘positive prayer sign’, and age
between 40-70 years. We did not include or exclude individuals in the DM group based on their
pain levels, and 13 study subjects with DM complained of some shoulder pain and 13 did not
have shoulder pain. Participants in the control group were matched for age, body mass index and
sex, did not have DM and did not have significant shoulder pain. Four participants in the control
group reported very low levels of pain and disability during their laboratory visit. Demographic
information is included in Table 1. The groups were well matched for age, body mass index, sex
and handedness.
Exclusion criteria for both groups were: history of/or current frozen shoulder, major rotator
cuff tears, recent upper extremity injuries, fractures, surgery in the thorax or arm, cervical pain,
thoracic outlet syndrome, rheumatic conditions, known connective tissue disorders, stroke,
severe skin allergies in areas to be tested, and allergy to adhesive tapes. In addition, participants
with body mass index higher than 35 kg/m2 were excluded because kinematic measurement
errors are known to be large in people with high body mass indices (20).
Eligible participants in both groups provided written informed consent. Participants
completed the Shoulder Pain and Disability Index (SPADI) and Disability of the Arm, Shoulder
and Hand (DASH) questionnaires to characterize the upper extremity pain and functional
limitations for descriptive purposes (21,22).
Shoulder 3D Kinematic measurements:
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The 3-dimensional position and orientation of the subjects’ bilateral humerus, scapula, and
thorax were tracked using the Flock of BirdsTM 3D electromagnetic tracking device (Ascension
Technology Inc., Burlington, VT, USA) and the MotionMonitor software (The Motion Monitor,
Innovative Sports Training Inc, Chicago IL, USA). Five Flock of Birds sensors were used. The
sensors were attached to the 1) thorax: mid sternum 2) right and left scapula: distal posterolateral
flat aspect of the acromion and 3) right and left arm: distal end of the humerus, via a
thermoplastic cuff secured with Coban (3M, St. Paul MN, USA) (20). Sensors and trailing wires
were taped down and secured with Coban to prevent slippage and motion artifact. Previous
studies for 3D scapular kinematics have demonstrated that the motion pattern obtained using
surface sensors was similar to acromion-fixed sensors, especially below 120° of elevation (23).
For humeral motion, the average error ranged from 0-4° for elevation angle and 1.7-2.3° for axial
rotation movements during scapular plane elevation movements when the motion was compared
for humerus bone fixed sensor and a sensor mounted on a thermoplastic cuff around the humerus
(20,24). The average error was larger for axial rotation movement by the side of the body than
with arm at 90° abduction (9.7-14.6°). To evaluate the reliability of these measures in individuals
with DM (N=7) in this study, we reattached the sensors at the end of the testing session. The
intra-class coefficient (ICC) (2,k) for glenohumeral rotation, scapulothoracic upward rotation,
and humerothoracic elevation during scapula plane elevation was between 0.84 – 0.97. The ICCs
for the rotation movements were between 0.71 – 0.97. For humeral motion, the average error
ranged from 1.0-2.1º and axial rotation error ranged from 1.7 -3.0º during scapular plane
elevation. The average error for axial rotation with arm adducted was 8.1-13.3º and with
abducted at 90 degree the error was 2.3-7.0º. An additional sensor attached to a stylus was used
for digitizing the anatomic coordinates. With arms relaxed, bony landmarks were digitized on the
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thorax, scapula and humerus to transform sensor data into local segment coordinates according to
the protocol recommended by the International Society of Biomechanics, Shoulder group (25).
Kinematic data was collected on both arms at 100 Hz for subjects’ full active range of motion
in scapular plane (40° anterior to the frontal plane) elevation, internal rotation (IR) and external
rotation (ER). The order of the movements was randomized. IR and ER data was collected in two
positions – elbow flexed at 90° with arm adducted (IR-AD and ER-AD) and elbow flexed at 90°
with arm abducted to 90° and forearm parallel to ground (IR-AB and ER-AB). The subjects were
instructed to bring the arm back to the starting positions during all the movements and to move
the arm as far as possible at a slow, steady self-selected speed. Five trials were performed on one
arm at a time for each movement with rest periods between trials. Averages of available ROMs
during two peak trials were used for data analysis.

Kinematic Data analysis:
Data were analyzed using the MotionMonitor software. Angles extracted during scapular
plane elevation were humerothoracic elevation, scapulothoracic upward rotation, and
glenohumeral external rotation. During the IR and ER movements, angles for glenohumeral axial
rotation were extracted. During scapular plane elevation, scapula position relative to the thorax
was defined as, internal/external rotation about a superior axis, upward/downward rotation about
the axis perpendicular to the plane of the scapula and anterior/posterior tilting about a laterally
directed axis (Euler angle sequence) (25,26). During scapular plane elevation and ER/IR
movements, the humerus position relative to the scapula was defined as, angle of elevation about
an anteriorly directed axis perpendicular to the medial to lateral epicondylar line, angle of
horizontal adduction/abduction (or flexion/extension) about a laterally directed axis parallel with
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the epicondylar line, and axial rotation about a superior axis directed towards the humeral head
center (Cardan angle sequence) (13,27). For all planar motions, results were analyzed at neutral,
30°, 60°, 90°, 120° and maximum humerothoracic elevation consistent with other methods
(15,26). For axial rotation with arm adducted and with arm abducted at 90°, the results were
analyzed at maximum ROM for external and internal rotation (20). Data for scapular plane
elevation, external rotation and scapulothoracic upward rotation were multiplied by -1 for easier
interpretation of the ROM data.

Statistical analyses
Statistical analyses of the data were performed using IBM SPSS (SPSS Inc, Chicago, IL) for
Windows (22.0). Descriptive statistics (means, standard deviations and percent changes) were
used to describe the variables. Student’s t-test and chi-square analysis were used to examine the
differences in the demographic variables. All variables were tested for their distribution and
appropriate statistics were used. We collected kinematic data on both shoulders. The ROM was
different for the left and right shoulders; therefore, data are represented for both upper
extremities (Table 2). We chose to represent the data as right/left versus involved/uninvolved
because complaints of shoulder pain were distributed equally in the DM group, and the groups
were matched for handedness. For scapular plane elevation motion, data were analyzed using a
two-way repeated measures analysis of variance (ANOVA), with the group (DM vs. control) and
angle (neutral, 30°, 60°, 90°, 120° and maximum humerothoracic elevation) as factors. The
outcome variables for scapular plane elevation motion included scapulothoracic upward rotation
and glenohumeral external rotation. Protected independent sample student’s t-test was used post-
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hoc to compare data if the ANOVA was significant. Peak humerothoracic elevation angle, IRAD, IR-AB, ER-AD and ER-AB data were compared between the two groups using independent
sample student’s t-test. Since we had 13 individuals with DM who had no pain, we conducted an
additional post-hoc analysis (t-test) to examine the movement differences between the nonpainful DM subgroup and the control group. Statistical significance was set at P<0.05.

RESULTS:
Demographic information is included in Table 1 for 26 participants in the DM group and 26
control participants. The groups were well matched for age, body mass index, sex and
handedness. The mean SPADI and DASH scores in individuals with DM were 21.4 (27.4) % and
19.4 (22.4) %, respectively, and in those without DM were 1.9 (3.5) and 2.6 (5.1) (P<0.01).
Scapular plane elevation: The peak humerothoracic elevation was decreased in individuals
with DM as compared to the controls on the right, 139 (12)º versus 150 (11)º and left shoulders,
122 (16)º versus 136.4 (11)º (P<0.05) (Fig 1). Glenohumeral ER increased with increasing
humerothoracic elevation angles for the right and left sides in both groups, as expected (main
effect of angle for right, F= 68.7, P<0.01; left, F= 37.1, P<0.01). The glenohumeral external
rotation angle was decreased in the DM groups as compared to the control group at 120° and
peak humerothoracic angle for the right side, and at 30°, 60°, 90° and peak humerothoracic
elevation for the left side (Table 2, Fig. 1), as indicated by the post-hoc t-tests performed under
the significant main effect of different angles between the two groups on the left and right side
(main effect for group for right, F= 4.2, P=0.045; left, F= 11.3, P<0.01). The groups started at
similar degrees of glenohumeral external rotation; however, the DM group had reduced ER for
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every 30 deg of increasing elevation angle, as indicated by the significant interaction effect
between angles and group for the right shoulder (F=5.1, P<0.01), but not significant for the left
glenohumeral ER (F=2.2, P=0.12). The scapulothoracic upward rotation increases with
increasing humerothoracic elevation angles for the right and left sides in both groups, as
expected (main effect of angle for right, F=429.4, P<0.01; left, F= 310.5, P<0.01) (Fig. 3). The
scapula upward rotation was not different between the DM and control group on the right and
left shoulder, as indicated by the interaction effect (right, F=3.1, P=0.052; left, F= 0.1, P=0.99)
and group effect (main effect for group for right, F= 4.2, P=0.63; left, F= 0.14, P=0.71).
Glenohumeral ER during scapular plane elevation was very similar in the DM sub groups with
and without pain (Fig 2). The DM sub-group with no pain (N=13) had decreased glenohumeral
external rotation angle at 60°, 90°, 120° and peak humerothoracic angle for the right side (Fig.
2), and at 30°, 60°, 90° and peak humerothoracic elevation for the left side as compared to the
control group (P<0.05). The scapulothoracic upward rotation was not different between the DM
sub-group without pain and control group.
Rotation: External rotation with arm adducted, ER-AD, was decreased on the right, 34.8
(17.4)° versus 52.2 (27.7)° and left, 33.9 (18.7)° versus 49.5 (23.6)° shoulders in individuals with
DM as compared to the control group (P<0.05) (Table 3). External rotation with arm abducted at
90°, ER-AB, was decreased on the right, 51.7 (16.4)° versus 71.1 (27.6)° and left, 48.3 (17.6)°
versus 70.7 (21.3)° shoulders respectively, in individuals with DM as compared to the control
group (P<0.05) (Table 3). IR-AD and IR-AB was not different between the two groups for both
sides. In the DM sub-group without pain, the ER-AD (right, 34.8 (13.1)°; left 33.3 (14.6)°) and
ER-AB (right, 51.2 (8.0)°; left 54.0 (16.6)°) were substantially reduced as compared to the
control group (P<0.05) but not different compared to the DM subgroup with pain.
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DISCUSSION:
The results of this study indicate that the glenohumeral external rotation and peak
humerothoracic elevation during scapular plane elevation were decreased by 11º - 16º and 10°14°, respectively in both shoulders in individuals with DM as compared to the control group. The
scapulothoracic upward rotation was not different between the two groups during scapular plane
elevation. Glenohumeral rotations, especially external rotation with arm adducted and abducted,
were reduced by 16-22° in people with DM as compared to controls. Surprisingly, similar LJM
changes were also seen in the DM subgroup that did not have complaints of shoulder pain (Fig.
2).
This is the first study to examine the three-dimensional kinematic differences in shoulder
movement in people with DM compared to controls. Shoulder LJM, as evidenced in this study,
may be a precursor to severe shoulder motion limitation, pain and disability. Previous research
has examined LJM at the shoulder in people with DM using traditional goniometric methods (68,11) and reported approximately 20 degrees of decrease in shoulder abduction motion and about
8 degrees of loss of external rotation motion. Results (unpublished) from a study in our lab also
found similar decreases in shoulder ROM, especially elevation (148° vs. 170°) and external
rotation motion (67° vs. 77°) in people with DM as compared to controls. The peak humerus
relative to thorax elevation was reduced by 10-14° in individuals with DM as compared to the
controls. Goniometric measurements are limited in scope to humerothoracic movements. Further,
the contributions of the humerus and scapula to the different movements are not known with
goniometry alone. The 3D analysis provides new understanding of shoulder LJM which has not
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been studied previously. With the use of 3D kinematics we were able to track glenohumeral
external rotation throughout the elevation range and not just at the end ranges. One of the main
findings of this study was the reduced glenohumeral external rotation observed throughout
increasing angles of humerothoracic elevation. Better understanding of specific movement
deficits can help in the development of exercise programs that target movements where ROM
loss is the greatest. Specific exercises to improve shoulder elevation and external rotation
throughout the ROM may help prevent future problems of severe LJM, pain and disability.
There was substantial loss of glenohumeral ER during the rotation movement in individuals
with DM as compared to the control participants (Table 3); internal rotation motion was not
different between the two groups. Surprisingly, reductions in external rotation of similar
magnitude have been reported in patients with idiopathic frozen shoulder, with humerus-toscapula external rotation. The ER with arm adducted (ER-AD) and abducted (ER-AB), limited to
34.7º and 45.3º, respectively, in patients with frozen shoulder as compared to the control group
(50.8º and 65.4º, respectively) (13). In another study, Rundquist et al. reported 14-16% decrease
in ER ROM in the involved shoulder of the patient as compared to the non-involved shoulder of
the same patient (14). While pain and shoulder disability characterize idiopathic frozen shoulder,
this study shows similar large deficits in the ER ROM in patients with DM, who did not have a
history of or current frozen shoulder and had not sought treatment for shoulder conditions.
Surprisingly, the glenohumeral ER ROM during elevation and rotation movements was
reduced even in individuals with DM who did not complain of pain (N=13) (Fig. 2). The
glenohumeral ER was reduced at almost all elevation angles, and ER-AD and ER-AB was
reduced in the DM sub-group with no pain as compared to the control group. The reductions in
ROM of the humerus relative to the scapula are observed before individuals with DM have
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symptoms of pain and/or disability. This finding strengthens our hypothesis that LJM of the
shoulder is an insidious process that is variably associated with pain.
One of the mechanisms for LJM is believed to be the excessive accumulation of advanced
glycation end-products (AGEs), formed by the non-enzymatic condensation of the metabolic
intermediates and glucose (3,9,10). The glycosylation process occurs in a variety of tissues, but
particularly those with high protein and collagen content like the tendons, skin, ligaments etc.,
and leads to collagen cross links in these tissues (28,29). The multi-step glycoslyation process is
irreversible in the later stages, and causes changes in the structural properties of tissues. This is
supported by clinical studies that have shown thicker biceps and supraspinatus tendons (30,31)
and thick fibrous capsule in the rotator interval area and thicker coracohumeral ligament in
people with DM compared to controls (32,33). We postulate that the reduction in ER ROM
observed in this cohort of patients with diabetes is due to the structural changes in the anterior
structures of the shoulder e.g. increased tendon thickness, anterior capsule changes, and ligament
changes. The supraspinatus assists in ER when the shoulder is abducted (34); therefore, we
speculate that the structural changes of the tendon may affect external rotation movement. The
coracohumeral ligament and rotator interval provide passive constraints to the ER ROM in the
adducted and abducted humerus position, respectively (35,36).
Contrary to our hypothesis, there were no differences in the scapulothoracic upward rotation
between the two groups. Previous studies have reported excessive scapulothoracic upward
rotation in individuals with frozen shoulder as a mechanism to compensate for glenohumeral
hypomobility. The peak scapulothoracic upward rotation was higher in the involved arm in
patients with idiopathic frozen shoulder as compared to the non-involved arm in these patients
(52.9° vs. 45.2°, P=0.006) (12,15,37). In this study, the peak scapula upward rotation was not
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different between the DM group and control group (Fig. 3, Table 2). The scapula is connected to
the thorax via muscular attachments and is highly mobile. We speculate the scapula upward
rotation was not decreased because of the lack of multiple tendon and ligament attachments
between the scapula and thorax, and therefore, not affected by systemic LJM in the same way
that the glenohumeral joint is affected.
This study provides unique insights about LJM at the shoulder joint in people with DM. If
these changes are identified and addressed early, appropriate interventions may help to prevent
severe upper extremity impairments, including limitation of ROM, pain and disability. In a study
by Diercks et al., outcomes were compared in two groups of patients with idiopathic frozen
shoulder, a group that received intensive physical therapy treatment and another group that
received general instruction for shoulder movement and patient education. At the end of the
study, pain, ROM and functional status were better for the group that received minimal
instruction (38). Decreased physical activity and use of arms may also be one the reasons for
LJM and movement impairments in individuals with DM. We speculate that an upper extremity
exercise program that incorporates simple ROM exercises and focuses on increasing overall use
of the arm may help reduce LJM in individuals with DM.
The examination of 3D shoulder kinematics is a powerful tool to examine LJM in individuals
with DM. However, some limitations must be acknowledged. Firstly, we excluded subjects with
body mass index greater than 35 kg/m2 to minimize shoulder kinematic measurement error.
Therefore, our results may not be generalized to all individuals with DM. We attached the
humerus sensors to thermoplastic cuffs versus directly on the skin to reduce errors due to
movement artifacts. However, this set-up may under represent the IR and ER motions because
the cuff may not fully track the humeral motion at end ROM. Lastly, the main focus of this study
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was to examine the differences between people with DM versus controls; however, the ROMs
were different between the right and left shoulders. We compared the right and left shoulder
ROMs in the DM group to right and left side of the control group. Preferential use of the
dominant arm may be one of the reasons for the higher ROMs on the right side, which was the
dominant arm for 84% of the individuals who participated in this study.
In conclusion, shoulder ROM was decreased in individuals with DM, even those without
pain. The glenohumeral external rotation was reduced by 11º - 16º throughout the elevation
motion in individuals with DM as compared to controls. The peak humerothoracic elevation was
decreased by 10º - 14º, and the external rotation, with arms adducted and abducted, was
decreased by 16º - 22º in the DM group compared to the controls. Movement impairments in
persons with diabetes are similar to those with idiopathic frozen shoulder, but with fewer
symptoms. Future research should focus on strategies to identify LJM in persons with diabetes
earlier and to develop prevention and treatment modalities to limit the associated disability.

Acknowledgements: The authors thank Victor Cheuy, Emily Martin, Lisa Simone and Molly
Burns for helping with data collection and analysis.
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Table 1. Demographic information
DM

Control

P value a

64.5 (5.6)

64.2 (5.8)

P = 0.8

Sex (M/F)

13/13

13/13

Height (m)

1.7 (0.1)

1.7 (1.0)

P = 1.0

Weight (kgs)

86.2 (15)

86.6 (12.7)

P = 0.8

BMI (kg/m2)

30.1 (4.1)

30.0 (4.0)

P = 0.9

HbA1c (%)

6.9 (1)

-

13.0 (4.3)

-

22/4

22/4
R=2
L=2

SPADI (%)

R=5
L=6
Both = 2
No pain = 13
21.4 (27.4)

1.9 (3.5)

P<0.01

DASH (%)

19.4 (22.4)

2.6 (5.1)

P<0.01

Prayer Sign

15/11

9/17

P = 0.164b

Age (y)

Diabetes duration (y)
Dominance (R/L)
Shoulder Problems (N)

(positive/negative)
All data represented as means (SD) or N.
a

Significance was determined using independent sample t-test student’s t-test

b

Significance was determined using chi-square analysis
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Table 2. Kinematic differences during scapular plane elevation motion
Humerothoracic Shoulder Scapulothoracic
Elevation
Upward Rotation
(deg)
(deg)

Glenohumeral External
Rotation
(deg)

DM

Control

DM

Control

P value a

5.4
(7.2)
5.2
(7.6)

2.3
(9.5)
5.2
(10.9)

14.2
(12.6)
10.6
(13.0)

16.0
(6.1)
16.5
(11.2)

0.66

6.1
(8.0)
7.2
(7.5)

4.8
(10.6)
7.8
(10.7)

15.4
(14.0)
12.7
(11.8)

19.2
(19.1)
24.6
(14.8) #

12.4
(9.5)
17.7
(9.0)

12.7
(11.9)
19.4
(10.7)

18.5
(17.2)
18.4
(12.1)

27.4
(19.5)
34.8
(19.5) #

22.8
(12.4)
33.2
(12.5)

26.1
(11.6)
35.3
(12.3)

23.5
(18.9)
25.4
(14.7)

33.8
(19.2)
40.8
(21.1) #

38.3
(12.8)
48.7
(16.8)

41.1
(12.3)
48.8
(13.9)

27.0
(17.9)
32.6
(17.5)

38.1
(19.4) *
45.0
(23.3)

0.04

47.1
(14.9)
L
47.6
(18.2)
All data represented as means (SD).

52.7
(14.8)
53.4
(15.7)

35.1
(21.9)
33.1
(15.4)

51.1
(22.9) *
49.4
(22.2) #

0.013

Neutral
R
L

0.086

30
R
L

0.41
0.002

60
R
L

0.09
0.001

90
R
L

0.06
0.004

120
R
L

0.07

Peak
R

a

0.003

Significance determined for glenohumeral external rotation using protected independent sample
student’s t-test since two-way repeated measures analysis of variance was significant.
*P<0.01; #P<0.05; R=Right; L=Left
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Table 3. Glenohumeral rotations
DM

Control

P value a

34.8
(17.4)
33.9
(18.7)

52.2
(27.7)
49.5
(23.6)

0.02

51.7
(16.4)
48.3
(17.6)

71.1
(27.6)
70.7
(21.3)

<0.01

16.8
(18.5)
14.9
(19.3)

22.0
(31.8)
19.0
(23.3)

0.28

0.8
-3.1
(25.5)
(25.7)
L
2.4
-3.4
(15.0)
(20.0)
All data represented as means (SD).

0.55

ER-AD (deg)
R
L

0.03

ER-AB (deg)
R
L

<0.01

IR-AD (deg)
R
L

0.36

IR-AB (deg)
R

a

0.27

Significance determined using independent sample student’s t-test.

ER=external rotation; IR=internal rotation; IR-AD, ER-AD= internal rotation and external
rotation with arm adducted; IR-AB, ER-AB= internal rotation and external rotation with arm
abducted at 90°
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Figure 1. Right glenohumeral external rotation during scapular plane elevation
80

*
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Humerothoracic Elevation (deg)

*P<0.05, Significance determined for glenohumeral external rotation using protected
independent sample student’s t-test since two-way repeated measures analysis of variance was
significant.
DM = Diabetes Mellitus
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Figure 2. Right glenohumeral external rotation (DM sub-group without pain) during scapular
plane elevation

Glenohumeral External Rotation (deg)
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*P<0.05, Significance based on post-hoc independent sample student’s t-tests to examine
difference between DM no-pain sub-group and control group
DM = Diabetes Mellitus
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Figure 3. Right scapulothoracic rotation during scapular plane elevation
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CHAPTER 4:
Relationship between Advanced Glycation End Products and Upper Extremity
Impairments in Individuals with Diabetes Mellitus

Shah KM, Clark BR, McGill JB, Lang CE, Maynard JD, Mueller MJ. Relationship between
advanced glycation end products and upper extremity impairments in individuals with diabetes
mellitus.
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ABSTRACT
OBJECTIVE Determine the differences and relationships between the Skin Intrinsic
Fluorescence (SIF), a proxy measure of advanced glycation end-products, biceps and
supraspinatus tendon thickness, upper extremity movement and disability in groups with and
without diabetes mellitus (DM).
RESEARCH DESIGN AND METHODS Fifty-two subjects participated; 26 with Type 2 DM
(13F/13M; Age 64.5 (5.6) yrs; BMI 30.1 (4.1) kg/m 2) and 26 sex, age and BMI matched
controls. The main outcome measures were: SIF; biceps and supraspinatus tendon thickness;
three- dimensional peak humerothoracic and peak glenohumeral external elevation; and
Disability of the Arm, Shoulder and Hand (DASH) questionnaires.
RESULTS Mean SIF measures were higher in the DM group as compared to the control group,
3.1 (1.4) AU versus 2.6 (0.6) AU (P<0.05). Biceps (4.7 (0.7) mm vs. 3.2 (0.8) mm) and
supraspinatus (6.4 (1.1) mm vs. 4.9 (1.2) mm) tendons were thicker, and peak humerothoracic
elevation and glenohumeral external rotation were reduced by 11° and 16°, respectively in the
DM group as compared to the control group (P<0.05). The SIF was correlated to biceps tendon
thickness, and DASH (r = 0.44-0.51, P<0.05), and negatively correlated to the peak
humerothoracic elevation (r = -0.44, P<0.05). The SIF score and shoulder strength explained
65% of the DASH scores (P<0.01).
CONCLUSIONS SIF, an indicator of advanced glycation end products, was related to tendon
thickness, shoulder movement impairments and disability. Clinicians should be aware that
accumulation of AGEs in individuals with DM may have deleterious effects on structural
changes, joint mobility and function of the upper extremity.
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Musculoskeletal complications associated with Diabetes Mellitus (DM) are frequent (1 -3)
and often lead to pain and disability (4). Limited joint mobility (LJM) at the hand and shoulder
are common impairments observed in the upper extremity (5-9). Prevalence of shoulder
impairments is reported to be about 11-50% in people with DM (4,10-13). However, the
underlying mechanism for this upper extremity LJM is not completely understood. It is
speculated that LJM is caused by the excessive accumulation of advanced glycation end products
(AGEs), formed by non-enzymatic condensation of excessive glucose and proteins (14-16).
These AGEs lead to collagen cross-links and structural changes in the tissues, of particular
interest is the cross linking in the collagen-rich musculoskeletal tissues i.e. tendons, ligaments,
skin, muscle etc (17-19). We speculate that this further leads to upper extremity movement
impairments and pain and disability. (Fig 1)
The AGEs that accumulate in the skin have an estimated half life of 15-20 years, and
therefore, are a better indicator of chronic hyperglycemia as compared to a single measure of
glycated hemoglobin which provides the glycemic exposure over 2-3 months (20,21). The skin
AGEs can be measured non-invasively using the SCOUT DS device (VeraLight Inc.,
Albuquerque, NM), which uses ultraviolet light to excite and measure the fluorescence produced
by AGEs (22-24). Previous research has shown that this in vivo, non-invasive measure of the
Skin Intrinsic Fluorescence (SIF) is correlated with the severity of tissue-specific diabetes related
complications such as neuropathy, increased arterial stiffness, and nephropathy (22,25,26).
However, the relationship between SIF and shoulder structural changes, LJM and upper
extremity function is unknown.
Some of the structural changes previously identified in diabetes include increased thickness
in the biceps and supraspinatus tendons (8,27,28). Additionally, fibrous contractures and dense
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collagen matrix have been observed in the shoulder joint capsule and adherence to the head of
the humerus, rotator interval area, and coracohumeral ligament (29,30). Studies that have
examined upper extremity joint mobility, especially using 3-dimensional (3D) kinematics are
lacking. Combined scapulothoracic and glenohumeral motion is necessary to complete overhead
reaching and tasks of daily living like grooming. These movements can be accurately quantified
and analyzed using 3D motion capture devices. However, no study, to the best of our knowledge,
has examined the relationships between these diverse metabolic and functional measures as they
relate to upper extremity musculoskeletal impairments.
The purpose of this study was to determine the differences and relationships between SIF (an
indicator of the AGEs accumulation in the skin), structural changes, and upper extremity
movement impairments and disability (Fig. 1). We hypothesize 1) the SIF measure will be
higher; the biceps and supraspinatus tendons will be thicker, and upper extremity movement will
be reduced in the DM group as compared to the control group; 2) the SIF measure will be
correlated to the tendon thickness and upper extremity disability, and negatively correlated to
shoulder movement; 3) a significant amount of the variance of the upper extremity disability will
be explained by the SIF, biceps tendon thickness, movement impairments and shoulder strength.
These variables were selected based upon the sequence of events illustrated in Fig 1.

RESEARCH DESIGN AND METHODS
We recruited a total of 52 subjects, 26 participants with Type 2 diabetes and 26 age, BMI and
sex matched controls, who agreed to participate in this study. Both groups were recruited from
the Washington University Diabetes Center and the Volunteers for Health database.
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The intent of this study was to recruit individuals attending an outpatient diabetes clinic
without acute or severe shoulder problems who were at high risk of developing shoulder LJM
and subsequent shoulder impairments. Characteristics associated with systemic LJM include
duration of diabetes (6,9-13) and the positive prayer sign; an inability to approximate the inter
phalangeal joints of the fingers (6). Therefore, inclusion criteria for the DM group were:
duration of diagnosed diabetes over 10 years or a ‘positive prayer sign’, and age between 40-70
years. We wanted to include the insidious development of shoulder impairments; therefore we
did not exclude individuals in the DM group based solely on their pain levels. To eliminate other
potential confounders, participants in the control group were matched for age, body mass index,
side of hand dominance, and sex.
Individuals in both groups were excluded if they had acute or severe shoulder problems
including a history of and/or current adhesive capsulitis, rotator cuff tears, recent upper extremity
injury and/or fractures, surgery in the upper extremity or thorax, neck pain, stroke with residual
upper extremity involvement, rheumatic conditions, hypothyroid malfunctions, angina and/or
other symptoms of myocardial ischaemia, severe skin allergies in area to be tested, known, or at
risk for, photosensitivity reactions and known connective tissue diseases. In addition, participants
with BMI over 35 kg/m2 were excluded as the kinematic measurement errors are known to be
large in people with high BMI (31).
All measurements were made by a single examiner during a single session on the right arm of
the individuals in the DM and control groups.
Skin Intrinsic Fluorescence (SIF): The SCOUT DS® device (VeraLight Inc., Albuquerque, NM)
was used to measure SIF non-invasively in the skin on the volar side of the forearm. Based on
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previous studies, the SIF was excited with an LED centered at 405 nm and detected over the
emission range of 441-482 nm. The skin reflectance was measured over the excitation and
emission range to accommodate for absorbance caused by melanin and hemoglobin (22 -24). The
correction equations were used as described by Conway et al. (22). The resulting SIF was
integrated over the 441-496 nm spectral regions to give the SIF sum. The intra subject skin
variation in SIF assessed by the SCOUT has been previously documented in 2,589 participants at
risk of developing type 2 DM (24). A mean of two consecutive measurements was used.
Tendon thickness: Ultrasound examination (US) (Acuson XP 128/10, Seimens medical
Solutions, Inc., Mountain View, CA, USA) for tendon thickness of the long head of the biceps
and supraspinatus was performed using a high resolution, multi-frequency (7-10 MHz) linear
transducer by a single examiner. Images of the transverse view and longitudinal view were
obtained for the biceps and supraspinatus, respectively, as described previously (27,28). The
tendon thickness was measured using ImageJ [version 1.45s (NIH, Bethseda, MD)]
computerized image analysis program. The maximum thickness of the biceps tendon in the
transverse view was measured within the bicipital groove of the humerus (Appendix, Figure 2).
In the longitudinal view, the maximum supraspinatus thickness was measured just in front of the
lateral part of the humeral head close to its insertion (anatomical neck) on the lesser tubercle. We
took an additional measurement at the midpoint of the anatomical footprint (greater tubercle of
the humerus) of the supraspinatus tendon to account for differences in the anatomy of the tendon
in between individuals (Appendix, Figure 3). The longitudinal thickness was an average of these
two measures. The intra-rater reliability for tendon thickness measurements taken a week apart
was 0.86 – 0.96. An average of three tendon thickness measurements for each tendon was used
for data analyses.
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Upper extremity movement: 3D humerothoracic (humerus relative to thorax) and glenohumeral
(humerus relative to scapula) joint motion was measured using Flock of Birds Electromagnetic
tracking device (Ascension Technology Inc., Burlington, VT, USA) and MotionMonitor
software (The Motion Monitor, Innovative Sports Training Inc, Chicago IL, USA). The humerus
sensor was attached to a thermoplastic cuff to reduce rotation errors and attached to the humerus
using tapes. Standard methods were used to build the anatomic segments and define the motion.
(32,33). Three trials were collected during full, pain-free active range of motion during scapular
plane elevation, defined as elevation in a plane 40° anterior to the frontal plane. The angles
extracted for this study were the peak humerothoracic elevation and peak glenohumeral external
rotation.
Shoulder flexor muscle strength: The isometric strength of the shoulder flexor muscles was
measured using a hand-held, digital strain-gauge dynamometer (Microfet ™, Hoggan Health,
UT). The patient was in supine position and standard stabilization and test positions were used
(34). An average of two trials was used for the data analysis.
Measure of upper extremity disability: We used the Disability of the Arm, Shoulder and Hand
(DASH) (35) self report questionnaire that has been used previously in the diabetes population
and has reported excellent reliability (4,12). The DASH has 30 questions, including questions on
disability as well as pain. The scores were calculated for a range between 0-100%, where a
higher number indicated more impairments. This self report questionnaire provides a
comprehensive assessment of the upper extremity pain and disability.

Statistical analyses:
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Statistical analyses of the data were performed using IBM SPSS (SPSS Inc, Chicago, IL) for
Windows (22.0). Descriptive statistics (means, standard deviations and percent changes) were
used to describe the variables. Differences in the demographic variables were analyzed using
independent sample student’s t-test and chi-square analysis. The mean peak humerothoracic
elevation and peak glenohumeral external rotation angles were converted to positive values for
ease of understanding. All variables were tested for their distribution and appropriate statistics
were used. For all variables included in the a-priori hypotheses, independent sample one-tailed
student’s t-tests were used to examine the differences between the two groups. Pearson’s
correlation coefficient was used to examine relationships between SIF and tendon thickness,
peak humerothoracic elevation and glenohumeral external rotation, and upper extremity pain and
disability. We further conducted a hierarchical multiple regression analysis to explain the
variance of the DASH scores. The variables of interest were the SIF scores, biceps tendon
thickness, peak glenohumeral external rotation and shoulder flexor muscle strength. These
variables were selected a - priori from the sequence of events described in Fig. 1. Shoulder
flexor muscle strength was added to the model because a combination of shoulder mobility and
strength is necessary for adequate upper extremity function. Statistical significance was set at
P<0.05.

RESULTS:
Demographic information is listed in Table 1. Data were collected on 26 participants with Type 2
DM (mean age 64.6 (5.6) y, BMI 30.1 (4.1) kg/m2, 13M/13F) and 26 age, BMI and sex matched
control participants. The mean DM duration was 13.0 (4.3) yrs and HbA1c was 6.9 (1.0) % or 52
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mmol/mol. Hand LJM, as indicated by the positive prayer sign was positive in15 individuals
with DM and 9 individuals without DM (P=0.164) (Table 1).
Differences between groups (Table. 2):
The mean SIF measure was higher in individuals with DM as compared to control
participants, 3.1 (1.4) Arbitrary Units versus 2.6 (0.6) Arbitrary Units. The biceps tendon and
supraspinatus tendon were 46.9% and 30.6% thicker, respectively, in the DM cohort as
compared to the non-DM controls. Peak external rotation and humerothoracic elevation were
decreased by 16° and 11°, respectively, and the shoulder flexors strength was reduced by 27% in
the DM as compared to the controls. The mean DASH score was 19.4 (22.4) % in people with
DM, indicating that these individuals had some complaints of upper extremity disability and
pain. Four control participants reported very low levels of pain and disability during their
laboratory visit (Table 2).
Relationships between SIF and tendon thickness, upper extremity movement, and pain and/or
disability:
The SIF measure was moderately correlated to the biceps tendon thickness (r = 0.44, P<0.05;
Fig 2a) but not correlated to the supraspinatus tendon thickness (r = 0.28, P= 0.2). The SIF
measure was negatively correlated to the humerothoracic elevation (r = -0.44, P<0.05; Fig 2b)
but not correlated to the glenohumeral external rotation (r = -0.32, P=0.13). The SIF measure
was not related to shoulder flexor muscle strength (r = 0.07, P=0.7). The SIF measure was
correlated to the DASH scores, a measure of upper extremity disability (r = 0.51, P<0.05, Fig.
2c).
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The SIF (R2 change = 0.26; P<0.01) and shoulder flexor muscle strength (R2 change = 0.39;
P<0.01) explained 65% of the variance of the DASH scores. The biceps tendon thickness and
peak glenohumeral external rotation were not included in the final model because the individual
contributions of these predictors were not significant.

CONCLUSIONS:
The results of this study demonstrate that the biceps and supraspinatus tendons were thicker,
and shoulder movements, especially humerus relative to scapula external rotation and muscle
strength, were substantially reduced in the DM group as compared to the age matched group
without DM. The skin intrinsic fluorescence (SIF), an indicator of advanced glycation endproducts (AGEs) accumulation was related to the biceps tendon thickness and upper extremity
disability, and negatively correlated to the peak humerothoracic elevation. This is the first study
to examine relationships between a proxy measure of AGEs, structural changes, and upper
extremity limited joint mobility and disability in people with DM.
The SIF measure was higher in individuals with DM as compared to controls in this study.
Reports place the SIF values about 17 – 33% higher in patients with DM as compared to the
control population (22,25,26). Previous studies have used SIF to understand the relationship
between accumulation of AGEs and diabetes related complications such as coronary artery
disease (25, 26) and polyneuropathy (22) in individuals with Type 1 and Type 2 DM. Further,
the non-invasive dermal SIF may be a better marker for understanding the musculoskeletal
complications in individuals with DM than blood or serum markers. The SIF has been reported
to be more strongly associated with the presence of neuropathy than the mean 18-year average of
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the HbA1c (22). In our study, the mean HbA1c values (single measure) were not related to any
of the key variables, including the SIF measure (r = 0.14, P = 0.5). In contrast, and as we had
predicted, the SIF measures were related to the tendon thickness, upper extremity movement and
pain and disability.
The biceps and supraspinatus tendons were considerably thicker in the DM group as
compared to the age, BMI and sex matched control group (Table 2). Previous work in this area
has shown similar results with biceps and supraspinatus tendons thicker in DM groups compared
to control groups (4.0 mm vs. 3.0-3.2 mm, and 6.2-6.6 mm vs. 4.9-5.2 mm, respectively) (27,28).
A unique contribution of our study is that the SIF measure was related to the biceps tendon
thickness, indicating that as the skin accumulation of AGEs increases the tendons tend to be
thicker. Although not measured in this study, the physical properties of the tendons are also
altered in individuals with DM. Tendon fiber sliding is decreased due to the AGEs accumulation
and collagen cross-links (36). AGE cross-link formation impacts the synthesis of the
extracellular matrix (37), further making the tissues stiff. Some of the other structural changes
include fibrous contractures in the capsule and coracohumeral ligament in the shoulders of
individuals with DM (29,30). This study provides unique insights in the relationship between the
in-vivo skin fluorescence and the tendon thickness which have not been examined previously.
We hypothesize that the changes in tendon thickness and other structures (i.e., shoulder capsule)
are a result of the accumulation of AGEs that leads to limited joint mobility and movement
impairments in the upper extremity (Fig 1).
There was substantial loss of peak glenohumeral external rotation (humerus relative to
scapula), humerothoracic (humerus relative to thorax), and shoulder flexor muscle strength in the
DM group as compared to the control group. Decreased elevation motion (about 20°) has been
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reported in people with DM using traditional goniometric methods of assessing range of motion
(7,8). A previous study in our laboratory (unpublished data) found similar decreases of about 22°
and 10° in the humerothoracic elevation and external rotation movement. We also observed
decreased flexor muscle strength in these individuals (10.9 kgs versus 14.7 kgs) in the DM group
and age, body mass index matched control group. High levels of AGE accumulation in older
adults has been associated with low grip strength values (38,39). Higher concentrations of AGEs
in the intramuscular connective tissue may contribute to decreases in muscle function and
increased disability. The SIF measure was negatively related to the peak humerothoracic
elevation, indicating that as the skin AGEs accumulation increases the movement decreases. We
hypothesized that a significant portion of the upper extremity disability would be explained by
the SIF, biceps tendon thickness, peak glenohumeral external rotation movement, and flexor
muscle strength. 65% of the variance in the DASH scores was explained by the SIF and shoulder
flexor muscle strength. Therefore, accumulation of AGEs and a decrease in shoulder flexor
muscle strength are important predictors of adverse outcomes of upper extremity disability.
Further exploration of these relationships, especially the relationship between self reported pain
and disability and AGES, is warranted in future studies.
Specific AGE receptors (RAGE) have been identified on the surface of chondrocytes,
tenocytes and fibroblasts (40) which when activated, lead to accelerated AGE cross link
formation in the collagen fibers of these tissues (17,18). The AGE-RAGE mechanism leads to
increased production of reactive oxygen species which further leads to increased inflammation
(41). This elevated inflammatory status in individuals with DM may manifest in complaints of
pain. Results from this study showing a strong relationship between SIF and upper extremity
disability and pain further strengthen this hypothesis. If impairments related to functional
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limitations are detected early, rehabilitation and pharmaceutical (AGE inhibiting and cross-link
breaking agents) therapies may be developed to help prevent additional detrimental changes.
Some limitations for this study are acknowledged. The SIF is a proxy measure of the skin
AGEs. Although not a direct measure of AGEs, in-vitro AGEs levels in porcine skin biopsy
samples have been related to the SIF measured using spectrometry (42). In this study, we only
assessed tendon thickness and not the intrinsic tendon quality such as histology, stiffness and
strength. Although, we evaluated tendon thickness in individuals with DM to see how it relates
to movement impairments, there are other factors (e.g. bone spurs, muscle stiffness, capsule
stiffness etc.) that may influence shoulder LJM. Kinematic measures are useful to examine 3D
shoulder movement; however, it does have a few limitations. Use of the humerus surface marker
mounted on a thermoplastic cuff may under estimate humerus motion, especially at end-range.
However, the difference between the surface marker versus bone pin marker for humerus motion
was only 0-4º for elevation angle and 1.7-2.3º for axial rotation movements (31). Since this was
a cross-sectional study design, we were not able to establish a cause-effect relationship. Also, we
do not have information about the temporal relationship of the risk of diabetes and development
of shoulder problems. Longitudinal studies are needed to clarify the causal relationship of these
variables. The groups were powered to examine differences between individuals with DM and
those without DM, but additional prospective studies with larger sample sizes are necessary to
confirm the findings of these relationships.
This study uniquely evaluated and determined differences and relationships between a proxy
measure of AGEs, upper extremity LJM and disability in individuals with DM as compared to
those without DM. In particular, the biceps and supraspinatus tendons were thicker by 46.9%
and 30.6%, respectively and shoulder movement, especially humerus relative to scapula external
84

rotation was reduced by 16 ° in individuals with DM as compared to the non-DM controls. The
other key finding of this study was that as the skin intrinsic fluorescence, a measure for AGEs
accumulation, increases, the tendons tend to be thicker, shoulder movement is reduced and
complaints of upper extremity disability and pain increase. It is crucial to understand the role of
AGEs on different tissues and their contributions to musculoskeletal impairments in DM. These
insights can help focus future interventions on the mechanisms of upper extremity
musculoskeletal problems in people with DM and develop targeted strategies to manage them.

Acknowledgements: The authors thank Victor Cheuy, Emily Martin, Lisa Simone and Molly
Burns for helping with data collection and analysis.
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Table 1 Demographic information
DM

Control

P-value a

64.5 (5.6)

64.2 (5.8)

P = 0.8

Sex (M/F)

13/13

13/13

Height (m)

1.7 (0.1)

1.7 (1.0)

P = 1.0

Weight (kgs)

86.2 (15)

86.6 (12.7)

P = 0.8

BMI (kg/m2)

30.1(4.1)

30.0(4.0)

P = 0.9

6.9 (1)

-

Age (y)

HbA1c

(%)
mmol/mol

Diabetes duration
(y)
Dominance (R/L)
Prayer Sign
(positive/negative)

52 (10.9)
13.0 (4.3)

-

22/4

22/4

15/11

9/17

P = 0.164 b

All data presented as means (SD) or N
a

Significance determined using independent sample student’s t-tests

b

Significance determined using chi-square analysis
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Table 2 Differences and relationships between the metabolic, structural and upper extremity
movement and function in groups with DM and without DM
DM

Control

P-value a

SIF (AU)

3.1 (1.4)

2.6 (0.6)

P = 0.047

BT Thickness
(mm)

4.7 (0.7)

3.2 (0.8)

P < 0.01

SST Thickness
(mm)

6.4 (1.1)

4.9 (1.2)

P < 0.01

Peak
Humerothoracic
Elevation (deg)

139 (12)

150 (11)

P < 0.01

35 (21)

51 (22)

P < 0.01

13.0 (3.9)

16.6 (4.7)

P < 0.01

19.4 (22.4)

2.6 (5.1)

P < 0.01

Peak
Glenohumeral
External Rotation
(deg)
Flexors Strength
(kgs)
DASH (%)

All data presented as means (SD)
a

Significance determined using independent sample student’s t-test (one tailed) to examine

group differences
*P < 0.05
DM = Diabetes Mellitus; SIF = Skin Intrinsic Fluorescence; DASH = Disability of the Arm,
Shoulder and Hand
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Figure 1. Theoretical framework for upper extremity impairments

Diabetes Mellitus

Accumulation of
Advanced
Glycation EndProducts

Structural changes

UE = Upper extremity
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UE movement
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UE pain and/or
disability

Figure 2.Correlations between SIF and Biceps Tendon thickness, peak humerothoracic elevation
and SPADI
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b)
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Correlations between Skin Intrinsic Fluorescence and a) Biceps tendon thickness, measured in
the bicipital groove (DM group, r = 0.44, P<0.05) b) peak humerothoracic elevation (DM group,
r = -0.44, P<0.05) c) DASH (DM group, r = 0.51, P<0.05).
Data analyzed using Pearson’s correlation coefficient.
DM = Diabetes mellitus; DASH = Disability of the Arm, Shoulder and Hand
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CHAPTER 5:
Summary of major findings
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Summary of Key Findings
The objectives of this research were to characterize the upper extremity movement
impairments and limited joint mobility (LJM) in people with diabetes mellitus (DM) and to
understand the relationships between advanced glycation end products, structural changes and
movement impairments on pain and disability in people with DM.
Chapter 2 asked the question: What is the severity of upper extremity pain/disability in a
group of people diagnosed with DM attending an outpatient diabetes clinic? What are the
specific impairments (shoulder and hand impairments) that may be associated with the upper
extremity pain/disability in people with DM? Our results indicate that a striking majority of the
patients with DM complained of shoulder pain and/or disability, and overall, a third of the
individuals with DM complained of moderate to high pain and/or disability. Goniometric
measurements of shoulder range of motion (ROM) indicate a decrease in all shoulder
movements, in particular external rotation and abduction as compared to age, body mass index
and sex matched control participants. Shoulder muscle strength and hand grip strength were
reduced in the DM group as compared to the non-DM controls. Hand limited joint mobility
(LJM) and decreased sensation were more severe and frequently present in the individuals with
DM as compared to the control cohort. Upper extremity LJM and strength deficits were related
to complaints of self reported pain and/or disability.
Chapter 3 asked the question: What are the differences in the shoulder kinematics,
humerothoracic, glenohumeral and scapulothoracic between people with DM and those without
DM? Our results show that the peak humerothoracic elevation was reduced in the DM group as
compared to the age, BMI and sex matched non-DM control group. We observed substantial loss

98

of glenohumeral motion; in particular, external rotation during elevation and rotation
movements. Contrary to our hypothesis, scapulothoracic motion was not reduced in the DM
group as compared to the non-DM group. We speculate that LJM related changes are much
higher at the glenohumeral joint owing to the extensive tendon and ligament attachments
between scapula and humerus as compared to the scapulothoracic joint which is formed by
muscle attachments.
Chapter 4 asked the question: What are the differences and relationships in the Skin
Intrinsic Fluorescence, a marker of advanced glycation end-product accumulation, biceps and
supraspinatus tendon thickness, shoulder LJM and strength, and upper extremity function in
people with DM versus non-DM controls? The skin intrinsic fluorescence was higher, biceps and
supraspinatus tendons were thicker, shoulder movement and strength were reduced, and the
upper extremity disability was higher in individuals with DM as compared to the control group.
The SIF measure was related to the biceps tendon thickness, peak elevation movement and upper
extremity disability and pain, measured via the Disability of the Arm, Shoulder and Hand
questionnaire. We had predicted that the SIF, biceps tendon thickness, peak external rotation
movement and flexor muscle strength would explain significant amount of variance in the
Disability of the Arm, Shoulder and Hand questionnaire scores (Figure 1, Chapter 1). However,
only the skin intrinsic fluorescence and flexor muscle strength added significant independent
variance to the model.
This strong association between the SIF measure and upper extremity disability and pain,
and strength, led us to rethink the a-priori linear relationship among the variables. Based on this
observation, we propose a revised model of shoulder impairments in individuals with DM
(Figure 1). We hypothesize that the AGEs accumulation in people with DM has a direct role to
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play in the pathogenesis of pain as opposed to our previous model. Advanced glycation end
products (AGEs) play an important role in the inflammatory pathways in DM. The AGE-specific
receptor (RAGE) leads to generation of reactive oxygen species, and attract inflammatory cells,
such as interleukin-2 (IL-2), polymorphonuclear leukocytes, lymphocytes and mononuclear
phagocytes. This in turn triggers the inflammatory pathways, and may contribute to the
propagation of a chronic inflammatory process (1,2). Previous research has shown the
importance of this pathway in diabetes complications like nephropathy, atherosclerosis etc.
Similarly, this AGE-RAGE interaction may contribute to the pathogenesis of diabetic
musculoskeletal complications as well. Increase in systemic inflammatory markers has
implications on joint pain (3); however, these mechanisms need to be explored further. Existing
information about the role of AGEs in inflammation, and results from this study further
strengthen our hypothesis about the possible role AGEs in patient reported complaints of pain
and disability.
In summary, our data indicate that shoulder and hand impairments are frequent, severe
and often associated with pain and disability. Shoulder LJM, in particular humerus relative to
scapula external rotation ROM, and strength deficits are significantly large in these individuals
with DM as compared to matched control participants. The SIF is an important biomarker for
AGEs and is related to structural changes, movement impairments and upper extremity function.

Limitations
There are several limitations to these studies including 1) sample size, 2) potential
selection bias of the groups, and the 3) cross-sectional nature of this study. First, studies with
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larger sample sizes are necessary to confirm the relationships between the clinical measures and
pain and/or disability in Chapter 2, and the SIF, upper extremity structure, and function measures
in Chapter 3. Secondly, we may have some selection bias in recruiting subjects for these studies.
In all these studies, we purposed to collect data from a representative sample of patients with
DM attending an outpatient diabetes clinic and who were at-risk for developing shoulder
problems. Therefore, the DM groups included participants with and without pain but did not
have any major shoulder pathology, such as rotator cuff tears and frozen shoulder. Interestingly,
the deficits in humerothoracic (measured using goniometry) and glenohumeral (measured via 3dimesional kinematics) movement, strength and hand function were seen regardless of their pain
status. Further, we had excluded individuals with high BMI (over 35 kg/m 2 ) to reduce the errors
associated to the kinematic measures (Chapters 3 and 4). Therefore, these results may not be
generalizable to all individuals with DM. We believe that shoulder impairments will be greater in
individuals with DM and high BMI because of greater detrimental effects of circulating AGEs
and inflammatory markers which are associated with obesity. Lastly, our studies used
correlational analyses to examine the relationships between SIF, structural changes, upper
extremity clinical measures, and pain and/or disability. We did not have data on the temporal
relationship between the risk of diabetes and development of shoulder problems. Prospective
studies our needed to examine the causal relationships.

Clinical Implications
Our research has shown that upper extremity impairments are prevalent in people with
diabetes. These studies, for the first time, show the relationship between an AGEs marker and
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functional measures as they relate to upper extremity impairments and LJM in people with DM.
Musculoskeletal conditions, in particular upper extremity impairments, are understudied. Health
care providers should focus on examination of these impairments as they are related to
complaints of pain and/or disability and may further lead to decreases in the quality of life. If
impairments related to functional limitations are detected early, rehabilitation and
pharmaceutical (AGE cross-link breaking agents) therapies may be developed to help prevent
additional detrimental changes (4-7).

Future Directions
Studies need to further explore the mechanisms related to musculoskeletal impairments in
people with diabetes and methods to prevent these impairments. The relationship between the
AGEs accumulation and structural changes needs additional examination. In this study, we only
explored the thickness of the shoulder tendons using ultrasound. Changes are seen in other
structures in the shoulder as well, including ligaments, capsule, muscle and bone (7 -10). The
impact of these structural changes on movement needs to be examined. Use of imaging tools can
help identify the quality of the shoulder structures and muscles, in-vivo. Examination of fatty
infiltration in the lower extremity muscles has been linked to decreased physical performance
(11). Similarly, we speculate that fat infiltration in the shoulder muscles may be linked to poor
performance of these muscles and functional deficits in the upper extremity. DM has been linked
to higher proportion of rotator cuff tears and poor outcomes after surgery (12-15). The
knowledge about tissue level mechanics and its influence on movement and healing may help
improve recovery post-surgery. Few studies have examined the physical and mechanical

102

properties of the tissues, in-vitro (16-18). Examination of tendon, muscle and bone properties at
the microscopic level has shown evidence of increased stiffness and decrease in the toughness.
Emphasis must be placed on relating these tissue level mechanics to joint function in people with
DM.
The effect of joint movement and exercise in the early stage of LJM in DM is not known.
Our results show that shoulder LJM changes start early and may not be related to complaints of
pain at the early stage. We postulate that the insidious loss of ROM and strength may hit a
“threshold” and manifest into severe symptoms of pain and/or disability. An exercise program
that focuses on improving the upper extremity ROM and overall use of the arm may be useful in
reducing LJM, strength deficits and pain/disability. The risk of developing frozen shoulder is
substantially higher in people with DM. Further, limited joint mobility may eventually manifest
in symptoms of frozen shoulder for some individuals with DM. Therefore, identifying these LJM
changes early may help prevent the sequelae of extreme pain, disability and joint limitation. A
number of non-operative treatment options have been suggested such as patient education,
modalities, exercises, joint mobilization and intra-articular corticosteroid injections (19,20).
However, results from a systematic review on the effectiveness of treatments for frozen shoulder
have shown that there is very limited clinical evidence about the best treatment option based on
the stage of the disease (21). In a study by Diercks et al., outcomes were compared in two groups
of patients with idiopathic frozen shoulder, a group that received intensive physical therapy
treatment and another group that received general instruction for shoulder movement and patient
education. At the end of the study, pain, ROM and functional status were better for the group that
received minimal instruction (22). Decreased physical activity and use of arms may also be one
the reasons for LJM and movement impairments in individuals with DM. We speculate that
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simple home based exercises in the early stages of LJM will not only reduce the limitations but
also prevent the onset of severe frozen shoulder like symptoms in people with DM. Results from
our study also suggest that emphasis must be placed on exercises that improve shoulder external
rotation and elevation motion.
Longitudinal studies are necessary to examine the course of DM and its impact on
accumulation of AGEs and shoulder joint mobility. In one of the few prospective studies of
shoulder disorders in DM, Laslett et al. reported that 45%, 81of 179 individuals with DM had
shoulder pain and/or disability, as measured via the SPADI. In a 12 month follow-up, 25% of
individuals who reported no pain and/ or disability at baseline developed clinically significant
pain or disability (10% points change on the SPADI) (23). Additionally, of the patients with preexisting pain and/or disability, 50% developed clinically significant worsening of pain and/or
disability. However, it is unknown if including an exercise program will help reduce LJM and
pain/disability, and prevent additional detrimental deficits in people with DM.
Pharmaceutical agents that are AGE-inhibitors or AGE-breakers such as aminoguanidine,
ALT-711, pyridoxamine and glucosamine have shown some promise in animal studies. These
have been useful in delaying the onset of the diabetic complications in animal models (24 -26).
Some of these drugs have been included in clinical trials; however, none have been approved yet.
Clinical trials that used aminoguanidine in types 1 and 2 DM in examining nephropathy
outcomes showed reductions in proteinuria and decrease in progression of retinopathy; however,
no significant beneficial effects were seen on the progression of nephropathy (27,28).
Alagebrium or ALT-711, which is an AGE breaker showed increased collagen solubility and
decreased RAGE in diabetic rats as compared to placebo treatment (29). In older humans, there
have been reports of improved vascular function (30). Further, pharmacological compounds that
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reverse or inhibit the effects of RAGE may help in reducing the effects of inflammation in the
pathogenesis of diabetes complications. Therapeutic treatments which counteract the detrimental
negative effects of the AGEs may become a part of clinical trials with subsequent transition to
clinical practice to control musculoskeletal changes in patients with DM
Overall, these studies have highlighted the important issue of upper extremity
musculoskeletal complications in people with DM. LJM, decreases in shoulder and hand
strength, pain and disability are severe in individuals with DM. Strikingly, LJM changes were
also observed in people with diabetes who did not have complaints of pain. These studies
provided insight into the possible mechanism and relationships between a marker of AGEs and
musculoskeletal complications. Increase in the accumulation of skin AGEs was related to
increased tendon thickness, decreased shoulder motion, and complains of disability. We
speculate that increasing levels of AGEs are a key cause of these musculoskeletal complications,
such as LJM, perhaps even directly contributing to inflammation and pain. The high correlation
between SIF and Disability of the Arm, Shoulder and Hand questionnaire scores (r = 0.51)
supports this speculation. The findings from these studies can help focus future interventions on
the mechanisms of upper extremity musculoskeletal problems in people with DM and help
develop targeted, exercise and pharmacological, strategies to manage them.
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Figure 1. New proposed model of upper extremity impairments in people with diabetes
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There was a strong association between the skin intrinsic fluorescence (SIF) measure (an
indicator of advanced glycation end-products) and upper extremity disability and pain, and
strength, which led us to rethink the a-priori linear relationship among the variables. Further,
advanced glycation end products play an important role in the inflammatory pathways in DM.
Based on these observations, we propose a revised model of shoulder impairments in individuals
with DM.
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Figure 1 Frequency distribution of SPADI scores
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Figure 2 – Biceps Tendon Ultrasound Image

a)

b)

Transverse view of the long head of biceps tendon. Solid yellow line indicates the maximum tendon thickness measured within the
bicipital groove of the humerus a) DM participant b) Control participant.
DM = Diabetes Mellitus
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Figure 3 – Supraspinatus Tendon Ultrasound Image

a)

b)

Longitudinal view of supraspinatus tendon thickness. Solid yellow line indicates measurement at the anatomical neck of the humerus,
dotted yellow line indicates measurement at the midpoint of the anatomical footprint of the supraspinatus tendon a) DM participant b)
Control participant.
DM = Diabetes Mellitus

114

